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ABSTRACT 
The hypothalamic peptide arginine vasopressin (AVP) is an important regulator of 
adrenocorticotropin (ACTH) release from the anterior pituitary. AVP stimulates 
ACTH secretion from corticotroph. cells by activating the Vlb AVP receptor, a mem-
ber of the G protein-coupled receptor (GPCR) family which activates the phospho-
inositide signalling pathway. In vivo, persistent or repeated stress can result in reduced 
ACTH responsiveness and it appears that regulation of the Vlb receptor plays an 
important role in this process. Similarly, repeated or prolonged stimulation of anterior 
pituitary cells with AVP in vitro results in a reduction in ACTH responsiveness, or 
desensitization. The aims of this study were to characterize this desensitization process 
and to investigate the mechanisms underlying it. 
Desensitization of the ACTH response to AVP was investigated in perifused dis-
persed ovine anterior pituitary cells. Desensitization was found to be rapid, readily 
reversible and occurred at relatively low AVP concentrations. Treatment with 5 nM 
AVP for 10 min reduced the response to a subsequent stimulation with 100 nM AVP 
by 39.4 ± 8.6%, but treatment for longer durations at this concentration did not 
increase the magnitude of desensitization. Recovery of responsiveness to a subsequent 
stimulation with AVP was complete within 40 min following pre-treatment with 
10 nM AVP for 15 min. Desensitization was found to occur at concentrations and 
VI 
durations of AVP pre-treatment which are within the range of endogenous AVP pulses, 
suggesting that it plays an important physiological role in the regulation of ACTH 
secretion. The very rapid kinetics of desensitization and resensitization of the ACTH 
response to AVP suggest that these processes are more important in regulating the 
acute response to AVP than the alterations of corticotroph responsiveness which have 
been observed during chronic stress. 
The characteristics of the desensitization process suggested that it might be caused 
by uncoupling of the pituitary AVP receptor from its signalling pathway, a common 
mechanism of desensitization amongst GPCRs which is often mediated by receptor 
phosphorylation. Investigations showed that the protein kinases protein kinase C 
(PKC) and casein kinase la, were not involved in desensitization. Activation of PKC 
by treatment with the diacylglycerol analogue 1,2-dioctanoyl-sn-glycerol did not result 
in desensitization and inhibition of PKC activity by treatment with Ro 31-8220 did 
not prevent AVP-induced desensitization. Similarly, treatment with the casein kinase 1 
inhibitor CKl-7 did not prevent AVP-induced desensitization. 
Receptor internalization and dephosphorylation by protein phosphatases are 
important in the resensitization of many GPCRs. Interestingly, pharmacological inhi-
bition of receptor internalization reduced the extent of desensitization which could be 
induced by AVP pre-treatment, suggesting that sequestration of receptors to an intra-
cellular compartment is important in the desensitization process. Inhibition of protein 
phosphatase 2B by treatment with FK506 slowed the rate of recovery following desen-
sitization, suggesting that this enzyme plays an important role in the resensitization 
process. No evidence could be found for the involvement of protein phosphatase 2A in 
resensitization of the ACTH response to AVP. 
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INTRODUCTION 
1.1 REGULATION OF PITUITARY ADRENOCORTICOTROPIN SECRETION 
DURING STRESS 
1.1.1 THE HYPOTHALAMO-PITUITARY-ADRENAL AXIS 
The survival and independent existence of higher animals is dependent upon their abil-
ity to maintain a constant internal milieu despite changes in their external environ-
ment. Adaptation to such external disturbances, or stress, requires the concerted action 
of a variety of behavioural, visceral and endocrine systems (Aguilera 1994). 
The key endocrine system involved in the vertebrate response to stress is the hypo-
thalamo-pituitary-adrenal (HPA) axis (Fig. 1.1). Exposure to a stressful stimulus is fol-
lowed by rapid increases in secretion of adrenocorticotropin (ACTH) by corticotroph 
cells of the anterior pituitary (Harbuz & Lightman 1992). Once released, ACTH is 
carried in the circulation to the adrenal cortex where it stimulates the release of gluco-
corticoid steroid hormones. These mediate the peripheral responses to stress Gohnson 
et al. 1992). The regulation of ACTH secretion from the anterior pituitary is a multi-
factorial process which is dependent largely upon hypothalamic neuropeptides that are 
carried to the pituitary in the hypophyseal portal circulation (Guillaume et al. 1992b). 
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Anterior 
Pituitary 
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INTRODUCTION 
Pituitary 
portal vessel 
Fig. 1.1. The HPA axis. CRH and AVP are synthesized in parvocellular neurons of the 
paraventricular nucleus and released from nerve terminals in the median eminence into the 
hypophyseal portal blood. AVP is also produced by magnocellular neurons of the paraventricu-
lar and supraoptic nuclei which project to the posterior pituitary and may release AVP as they 
pass through the median eminence. AVP and CRH stimulate ACTH secretion from corti-
cotrophs of the anterior pituitary. ACTH induces the release of glucocorticoids from the adre-
nal cortex. 
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While a number of hypothalamic factors are capable of acutely stimulating ACTH 
secretion, the two most potent secretagogues are corticotropin-releasing hormone 
(CRH) and arginine vasopressin (AVP). These interact with specific receptors located 
in the plasma membrane of the pituitary corticotroph, thereby stimulating ACTH 
secretion (Aguilera 1994). 
During adaptation to chronic stress pituitary ACTH responses undergo regulatory 
changes (Aguilera 1994). While a variety of mechanisms may be responsible for these 
changes it has been suggested that because there is a good correlation between ACTH 
responsiveness and pituitary AVP receptor content, regulation of this receptor may be 
particularly important in controlling the ACTH responsiveness of corticotrophs (Agui-
lera et al1994). Commonly; the response of hormone receptors is regulated by negative 
feedback loops within the cell which result in a desensitization of the response to either 
a repeated or continuous stimulus (Lohse 1993). In vitro studies have shown that the 
ACTH response of pituitary cells to AVP is desensitized following prolonged exposure 
to AVP, however this process is poorly characterized and the molecular mechanisms 
involved are unknown (Holmes et al 1984; Evans et al 1988). The aims of this study 
were to use an in vitro approach to characterize the desensitization of the ACTH 
response to AVP in ovine anterior pituitary cells and to investigate the mechanisms 
involved in this process. 
1.1.2 VASOPRESSINERGIC CONTROL OF ACTH SECRETION 
Although it has been known since the 1950s that AVP is capable of stimulating ACTH 
release from the anterior pituitary (e.g. see Martini & Morpurgo 1955) it is only rela-
tively recently that the important physiological role played by this neuropeptide in the 
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HPA axis has become clear. Previously attention had been focused on CRH as the 
physiological regulator of ACTH secretion (Antoni 1993). 
Two types of hypothalamic neuron are capable of producing and secreting AVP: 
magnocellular neurons of the supraoptic and paraventricular nuclei and parvocellular 
CRH neurons of the paraventricular nuclei (Antoni 1993). There are two types of par-
vocellular CRH neuron, one containing CRH only, and a second in which CRH and 
AVP are co-localized (Whitnall et al. 1985; Sawchenko et al. 1984), apparently within 
the same secretory vesicles (Whitnall et al. 1987). While magnocellular AVP may be 
responsible for increased ACTH secretion during some acute stress conditions (e.g. 
saline infusion [Irvine et al. 1989]) most evidence suggests that A VP from parvocellular 
neurons, in combination with CRR, is responsible for the regulation of ACTH secre-
tion during chronic stress (Aguilera 1994). 
Exposure to a variety of different types of stress has been shown to increase the 
secretion of AVP into the hypophyseal portal circulation. In experiments conducted 
with conscious, unrestrained sheep insulin-induced hypoglycaemia (Engler et al. 1989; 
Caraty et al. 1990), audiovisual stress (Engler et al. 1989), acute haemorrhagic stress 
(Caraty et al. 1988), anaesthesia (Engler et al. 1989) and endotoxin treatment (Battaglia 
et al. 1998) all caused pulsatile secretion of AVP into the portal circulation and these 
increases were associated with elevated ACTH concentrations in systemic blood. These 
observations are consistent with the hypothesis that AVP is involved in the regulation 
of ACTH secretion from the anterior pituitary. Similar patterns of hormone secretion 
have been shown to occur during stress in the rat (Plotsky et al. 1985a; Plotsky et al. 
1985b), monkey (Zimmerman etal. 1973) and horse (Alexander etal. 1991; Alexander 
et al. 1994). 
4 
INTRODUCTION 
Blockade of the action of Avp, either through neutralization using specific anti-
bodies or treatment with selective AVP antagonists, has firmly established that endoge-
nous AVP plays a physiological role in the regulation of ACTH secretion. Using an 
anti-AVP antibody Guillaume et al (1992b) selectively immunoneutralized AVP in 
intact rams. This treatment significantly reduced the ACTH and cortisol responses to 
two types of stress (insulin-induced hypoglycaemia and isolation-restraint). Similar 
reductions in the ACTH response to both restraint and formalin stress were observed 
in anti-AVP immunoneutralized rats (Linton et al 1985). In the rat, treatment with 
the vasopressin antagonist 1-deaminopenicillamine-2-( O-methy"tyrosine vasopressin 
reduces the ACTH response to insulin-induced hypoglycaemia (Plotsky et al. 1985b) 
and haemorrhagic stress (Plotsky et al 1985a). Additionally, the ACTH and cortisol 
responses to stress in Brattleboro rats, which are genetically lacking in AVP, are signifi-
cantly reduced compared to the response observed in normal rats. (Conte-DeVolx et al. 
1982). 
In many instances the secretion of CRH and AVP into the hypophyseal portal cir-
culation occurs simultaneously (Engler et ai. 1989). Although the data described above 
indicate a role for AVP in the regulation of ACTH secretion, its relative importance 
and in particular its interaction with CRH remain a matter of debate. The ability of the 
two hormones to stimulate ACTH secretion in vitro appears to vary depending on the 
species. In both the rat (Vale et ai. 1983; Watanabe & Orth 1988) and horse (Evans et 
aL 1993) CRH is a much more potent ACTH secretagogue than AVP. There is a 
degree of controversy regarding the relative importance of the two hormones in the reg-
ulation of ACTH secretion in the sheep (McFarlane et ai. 1995). Familari et ai. (1989) 
found that AVP was considerably more potent than CRH whereas Evans et ai. (1988) 
reported that AVP was less potent than CRH. In all cases a marked synergism has been 
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observed to occur both in vivo and in vitro (Evans et al. 1996). That is, when CRH and 
AVP are given together ACTH output is greater than the added effect of each hor-
mone alone (see Antoni ]1986] for review). 
It has been proposed that this synergism may allow CRH to function as a permis-
sive signal, setting the overall responsiveness of the corticotroph, while A VP is the 
main dynamic hypothalamic ACTH-releasing factor (Antoni 1993). ACTH is released 
into the portal circulation in a pulsatile manner with two main independent rhythms: 
one with short duration and a frequency of approximately 3/h and another with ultra-
dian rhythm of approximately 2 h (Carnes et al. 1989). Studies in the sheep in which 
the two hormones are immunoneutralized have shown that CRH and A VP have differ-
ent effects on these rhythms. Basal ACTH secretion and the number and mean ampli-
tude of ACTH pulses were reduced following immunoneutralization of CRH but were 
unaffected by immunoneutralization of AVP. In both instances the responses to acute 
stress were reduced (Guillaume et al. 1992a; Guillaume et al. 1992b). In the rat admin-
istration of a CRH antagonist reduced mean plasma ACTH levels without affecting 
pulse frequency and duration of the pulses, whereas an AVP antagonist reduced fre-
quency and duration of the pulses but not mean ACTH values (Negro-Vilar et al. 
1987). Also, short term changes in ACTH secretion have been found to correlate more 
closely with AVP release than with CRH release in the horse. Using a novel technique, 
Alexander et al. (1991) sampled pituitary venous blood from conscious, unanaesthe-
tized horses at intervals of approximately 30 s during acute exercise. A brief high-speed 
gallop was found to cause a transient increase in ACTH secretion which occurred at 
the same time as A VP secretion, while CRH levels were unchanged. Similarly; in the 
resting horse there is a very close and consistent relationship between the secretion of 
micropulses of AVP from the hypothalamus and the secretion of ACTH from the pitu-
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itary, suggesting that AVP is the primary signal for pulsatile secretion of ACTH (Alex-
ander et al. 1994). 
In addition to the stimulatory effects of hypothalamic factors such as CRH and 
Avp, the HPA axis is under negative feedback regulation by glucocorticoids (Keller-
Wood & Dallman 1984). At the hypothalamus both expression and release of CRH 
and AVP are inhibited (Spinedi etal. 1991; Ma & Aguilera 1999), and at the pituitary 
POMC transcription and ACTH secretion are inhibited (Levin & Roberts 1991). As 
such, removal of glucocorticoid negative feedback by adrenalectomy results in a marked 
activation of the HPA axis with increases in secretion of CRH, AVP and ACTH 
(Aguilera 1994). 
1.1.3 MECHANISMS OF AVP-STIMULATED ACTH SECRETION 
As described above, the main targets of AVP and CRH in the anterior pituitary are the 
ACTH -producing corticotrophs. Most investigations into the mechanisms of hor-
mone-stimulated ACTH secretion have been carried out in vitro using one of four 
experimental systems: primary cultures of dispersed anterior pituitary cells, acutely pre-
pared isolated cells, anterior pituitary segments or corticotroph adenoma cells (most 
commonly the ACTH-secreting AtT-20 mouse tumour cell line) (Watanab e & Orth 
1988; Antoni 1993). These studies have shown that both AVP and CRH bind to 
specific, distinct cell surface receptors, thereby triggering intracellular signalling cas-
cades which ultimately result in increased secretion of ACTH (Antoni 1993). Binding 
of AVP to its receptor results in activation of the phosphoinositide signalling pathway 
(see Fig. 1.2), whereas the CRH receptor is coupled to adenylate cyclase (see King & 
Baertschi 1990 for review). 
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• 
•• ACTH 
Fig. 1.2, Diagrammatic representation of the intracellular signalling pathways involved in the 
regulation of AVP-stimulated ACTH secretion from the pituitary corticotroph. Binding of 
AVP to its specific cell surface receptor (1) causes the a and ~y subunits of G q to dissociate (2), 
with Gqa going on to activate phospholipase C (PLC)(3). PLC hydrolyzes the membrane lipid 
phosphatidylinositol-4,5-bisphosphate (PIP2) to inositol trisphosphate (IP3) and 
diacylglycerol (4), Both IP3 and DAG promote an increase in intracellular free Ca2+-IP3 
causes Ca2+ to be released from intracellular stores (5) while DAG increases intracellular Ca2+ 
via the activation of protein kinase C (PKC)(6). This increase in intracellular C~+ results in the 
exocytosis of ACTH (7). 
8 
INTRODUCTION 
1.1.3.1 PITUITARY AVP RECEPTORS 
In addition to stimulating ACTH secretion from the anterior pituitary, AVP has a 
number of other effects on a variety of tissues. In the kidney it has an antidiuretic effect, 
promoting water reabsorption, in the vasculature it has a pressor effect, while in the 
liver it promotes glycogenolysis (U.szlo et al. 1991). The different effects of AVP are 
mediated by three structurally and pharmacologically distinct receptors. All three are G 
protein-coupled receptors (GPCRs) and share the characteristic structure of this recep-
tor family, i.e. a single polypeptide chain with seven transmembrane domains (De 
Keyzer et al. 1994). 
Two groups of AVP receptors have been distinguished on both functional and 
pharmacological bases. V2 receptors are found in the kidney and mediate their effects 
via activation of adenylate cyclase and subsequent production of the intracellular second 
messenger cyclic AMP (cAMP)(Birnbaumer et al. 1992). In contrast the VI receptors 
mediate signal transduction via activation of phospholipase C (PLC) and the phospho-
inositide signalling pathway (Watson & Arkinstall 1994). There are two subtypes of VI 
receptors: the VIa receptor which is found at high levels in vascular smooth muscle 
cells and liver (Morel et al. 1992) and the Vlb (also known as V3) receptor found in the 
pituitary (De Keyzer et al. 1994). While the two receptors activate the same signalling 
pathway they are pharmacologically and structurally different (De Keyzer et al. 1994). 
Baertschi & Friedli (1985) first postulated the presence of a pituitary VI receptor sub-
type based upon the lack of effect of the antipressor agonists dPTyr(Me)AVP and 
d(CH2)sTyr(Me)AVP on AVP potentiation of the ACTH response to CRH. This 
hypothesis was supported by investigations in which the efficaciousness of a greater 
variety of antagonists on pituitary, hepatic and kidney A VP receptors were compared 
Card et al. 1986). More recently the Vlb receptors from the human (De Keyzer et al. 
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1994; Sugimoto et al. 1994), rat (Lolait et al. 1995) and mouse (Ventura et al. 1999) 
have been cloned. The putative amino acid sequence of the human V1b receptor has a 
relatively high degree of sequence identity with the human V1a, oxytocin and V2 
receptors (45.5, 44.8 and 37.3% respectively), and also with members of the AVP 
receptor family in other species (De Keyzer et al 1994). For example, the human and 
mouse V1b receptors share 81% amino acid identity (Ventura etal. 1999). 
1.1.3.2 ACTIVATION OF THE PHOSPHOINOSITlDE SIGNALLING PATHWAY BY AVP 
The intracellular effects of many extracellular signals are mediated by the phospho-
inositide signalling system (Berridge & Irvine 1984). In this pathway the twin intracel-
lular second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
are produced by hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), a minor 
lipid constituent of the plasma membrane, by the effector enzyme PLC (Michell 
1992). Involvement of this signalling pathway in AVP-stimulated ACTH secretion is 
well established: treatment of rat pituitary cells with AVP results in increased 
phosphatidylinositol turnover (Raymond et al. 1985) and accumulation of inositol 
phosphates (Todd & Lightman 1987) both of which are markers of increased PIP2 
hydrolysis. 
GPCRs regulate the activity of the ~ isoform of PLC via G proteins of the G q/ll 
class (Katan 1996). Binding of a ligand to the extracellular face of its receptor induces a 
conformational change which allows the intracellular loops and tail of the receptor to 
interact with the trim eric G q/ll protein. The ex and ~'Y subunits of the G protein disso-
ciate, with the Gqa subunit going on to activate PLC-~ (Strader 1994). Although it is 
clear that the V1b receptor couples to Gq/ ll (De Keyzer et al 1994) the molecular 
mechanisms involved in this interaction are unknown. It seems likely, however, that the 
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mechanisms are similar to those involved in the coupling of the Via receptor to Gqll1> 
which is the result of an interaction between the G protein and the second intracellular 
loop of the receptor (Liu & Wess 1996). 
As described above, hydrolysis of PIP2 produces the twin intracellular second 
messengers IP3 and DAG. Ultimately, both of these molecules stimulate ACTH secre-
tion by increasing the concentration of intracellular free Ca2+ (King & Baertschi 1990). 
IP3 is a highly charged molecule and, once produced, diffuses away from the membrane 
to the cytoplasm where it mediates the release of Ca2+ from internal stores (Berridge & 
Irvine 1984). In contrast to IP 3, DAG remains in the plasma membrane and activates 
the enzyme protein kinase C (PKC)(Nishizuka 1984). The involvement ofPKC in the 
AVP-induced ACTH response is well documented. Treatment of cells with phorbol 
esters, which directly activate PKC (Castagna et al. 1982), and DAG analogues which 
have a similar effect (Ebeling et al 1985), stimulate the secretion of ACTH from ante-
rior pituitary cells (Won et al. 1990; Abou-Samra et al. 1986; Liu et al. 1990). Further-
more, both down-regulation (Carvallo & Aguilera 1989; Koch & Lutz-Bucher 1991) 
and inhibition (Koch & Lutz-Bucher 1991) of PKC reduce AVP-stimulated ACTH 
secretion. Although the intracellular targets of PKC phosphorylation are still to be 
identified (Liu 1994; Liu etal1994), the effects ofPKC activation on ACTH secretion 
appear to be dependent upon an influx of extracellular Ca2+ through L-type voltage-
stimulated Ca2+ channels (L-VSCC)(Abou-Samra et al 1987; Won et al. 1990; Cor-
cuff et al. 1993; Le Beau & Mason 1994). It has been suggested that PKC might 
enhance Ca2+ entry through L-VSCC by directly phosphorylating the channels 
(Le Beau & Mason 1998). 
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1.2 ATTENUATION OF SIGNALLING: DESENSITIZATION 
Commonly, stimulation of a target cell by a hormone not only elicits the characteristic 
cellular response but also regulates the components of the intracellular signalling path-
way involved, thereby modifying the response to a subsequent exposure to the hormone 
(Catt et al. 1979). In many systems, responsiveness is reduced following exposure to 
either a long-lasting or repeated stimulus (Lohse 1993). This reduction in responsive-
ness, or desensitization, is a commonly observed feature of signalling mediated by 
GPCRs (Grady et al 1997). Although desensitization of signalling through GPCRs 
can be achieved by regulatory mechanisms operating at many levels in the signalling 
pathway, those which are involved in the regulation of the receptor appear to account 
for most desensitization (Krupnick & Benovic 1998). 
Mechanistically, desensitization processes can be divided into two groups: those 
which affect the ability of a receptor to activate its signalling pathway (often known as 
uncoupling) and those which affect receptor number (often known as down-regula-
tion). Mechanisms in the first category are generally rapid, occurring within minutes of 
the onset of the stimulus, and reduce responsiveness by preventing the receptor from 
transducing the signal, i.e. uncoupling it from its intracellular signalling pathway. In 
contrast, those in the second are comparatively slow, taking place over periods of hours 
to days, with the reduced response being the result of a reduction in the total number of 
receptors (Lohse 1993). 
1.2.1 RECEPTOR PHOSPHORYLATION 
Uncoupling of GPCRs from their signalling pathways is commonly achieved by phos-
phorylation of receptors on one or more intracellular domains (Ferguson et al 1996b). 
Phosphorylation of these domains either direcdy or indirectly inhibits the interaction 
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between the receptor and its G protein, thereby diminishing the agonist-induced 
response (Pitcher et al 1998). 
A number of different protein kinases are able to phosphorylate GPCRs. Amongst 
the most important and best studied of these are the G protein-coupled receptor 
kinases (GRKs). The hallmark characteristic of this family of serine/threonine kinases 
is that they preferentially phosphorylate activated (i.e. agonist-bound) receptors (Pre-
mont et al. 1995). Interaction of a G RK with a receptor results in a potent activation of 
the kinase (Pitcher et al. 1998), allowing it to phosphorylate specific residues in either 
the C-terminal tail (e.g. the ~2-adrenergic receptor [Fredericks et al. 1996]) or the third 
intracellular loop (e.g. the m2 muscarinic receptor [Nakata et al1994] and the aradre-
nergic receptor [Eason et al. 1995]) 'Of the receptor. Phosphorylation at these sites by a 
GRK is not in itself sufficient to fully inactivate the receptor (Benovic et al. 1987a). 
Instead, GRK-mediated phosphorylation enhances 10 to 30-fold the binding to the 
receptor of a class of cytoplasmic inhibitory proteins known as arrestins (Lohse et al. 
1992). Binding of an arrestin molecule to the receptor prevents receptor-G protein 
interactions from taking place, resulting in termination of signalling (Lohse et al. 
1990b). 
Seven mammalian GRKs have been identified: GRKl (also known as rhodopsin 
kinase), GRK2 (~-adrenergic receptor kinase-i), GRIG (~-adrenergic receptor kinase-
2), GRK4 (IT-ll), GRK5, GRK6 and GRK7 (Ferguson 2001). With the exception of 
GRKl and GRK7, which are found almost exclusively in the retina (Lorenz et al. 1991; 
Weiss et al. 1998), and GRK4, which is found in testis (Premont et al. 1996), the GRKs 
are ubiquitously expressed (Freedman & Lefkowitz 1996). Each of the GRKs is able to 
phosphorylate many distinct GPCRs although there appears to be no obvious correla-
tion of GRK specificity with any particular receptor or class of receptors (Premont et al. 
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1995). For example, GRK2 phosphorylates not only the Pn Pr, a2A - and a2B-adren-
ergic receptors but also the distantly related ml, m2 and m3 muscarinic receptors, the 
Dl dopaminergic receptor and the NK 1 neurokinin receptor (Bohm et al. 1997). Simi-
1arly, there appears to be no clear consensus sequence within the receptor substrates for 
GRK-mediated phosphorylation, although in some instances the putative phosphory-
lation sites have pairs of acidic residues located at the amino-terminal side of the phos-
phorylated serine or threonine residue (Ohguro et al. 1993; Prossnitz et al. 1995; Eason 
et al. 1995; Fredericks et al. 1996). 
Because the GRKs only phosphorylate agonist-occupied receptors, desensitization 
through this mechanism is receptor-specific, or homologous, with the cellular 
responses to other stimuli being unaffected (Premont et al 1995). Many GPCRs are 
phosphorylated by their effector kinases, namely protein kinase A (PKA) and PKC. 
This type of desensitizing phosphorylation results in a direct negative feedback in 
which the effector enzyme turns off its own stimulation. However, because the effector 
kinases are able to phosphorylate receptors which are not agonist-occupied this mecha-
nism of desensitization allows for a generalized, or heterologous, form of desensitiza-
tion in which exposure to one agonist can result in the desensitization of responses to 
another (Lohse 1993). However, it should be noted that although it is not obligatory 
for its phosphorylation and desensitization by the effector kinases, agonist-occupancy 
of the PTadrenergic receptor increases the rate of phosphorylation of the receptor by 
PKA in vitro (Benovic etal. 1985). 
The mechanisms of heterologous desensitization are best understood for the Pr 
adrenergic receptor. This receptor contains two consensus sites for phosphorylation by 
PKA (Blake et al. 1987; Bouvier et al. 1989), one in the third intracellular loop, a region 
that is essential for coupling to Gs' and the other at the amino-terminal part of the car-
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boX)rl-terminal tail of the receptor, which also appears to be important in receptor-Gs 
coupling (Strader et at. 1987; Okamoto et al. 1991). PKC is also able to phosphorylate 
the ~radrenergic receptor, probably at the same sites that are utilized by PKA (Pitcher 
et at. 1992; Bouvier et al. 1987; Johnson et al. 1990). Phosphorylation at these sites does 
not enhance binding of arrestin to the receptor and this protein does not appear to be 
involved in this desensitization process (Pitcher et al. 1992; Lohse et al. 1992). Indeed 
it appears that, unlike GRK-mediated phosphorylation, phosphorylation of the ~T 
adrenergic receptor by PKA and PKC is, in itself, sufficient to induce receptor desensi-
tization, presumably because phosphorylation in these coupling regions impairs the 
ability of the receptor to activate Gs (Okamoto et al. 1991; Pitcher et at. 1992). 
In addition to the ~Tadrenergic receptor a variety of other receptors have been 
shown to be desensitized by their effector kinases. For example, phosphorylation by 
PKA results in desensitization of the D i dopamine receptor (Bates et al. 1991) and the 
PGE1 prostaglandin receptor (Clark et at. 1988) while PKC-mediated phosphorylation 
has been shown to result in desensitization of the 5HT 2 serotonin receptor (Smit et at. 
1992) and the ATiA angiotensin II receptor (Oppermann et at. 1996; Zhang et al. 
1996). However, many receptors do not undergo desensitization by their effector 
kinases, e.g. in contrast to the ~radrenergic receptor, the ~3-adrenergic receptor does 
not undergo PKA-mediated desensitization (Nantel etal. 1993). 
Although the maximal extent of desensitization which can be induced by the 
GRKs and effector kinases is similar (50-70% and 20-50% respectively [Lohse 1993J) 
there are important differences in the characteristics of the two mechanisms of desensi-
tization. Firstly, although both mechanisms of desensitization are considered to be 
rapid, GRK-mediated desensitization is much faster than effector kinase-mediated 
desensitization. For example, desensitization of the ~Tadrenergic receptor by GRK2 
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occurs with a tlh <15 s compared with desensitization by PKA which occurs with a % of 
3.5 min (Roth et al 1991). Secondly, desensitization by the effector kinases is much 
more sensitive to agonist concentrations. For example, PKA-mediated desensitization 
of the Pradrenergic receptor occurs at concentrations 100-fold lower than GRK-medi-
ated desensitization (Clark et al. 1988; Hausdorff et al. 1989; Lohse et al. 1990a). These 
characteristics have suggested that GRK-mediated desensitization may be most impor-
tant in the regulation of receptor function in rapidly changing environments where 
agonist concentrations are high, such as the synaptic cleft (Roth et al. 1991). 
The PLC-coupled m3 muscarinic receptor has been shown to undergo desensiti-
zation within seconds of agonist exposure (Tobin & Nahorski 1993). This desensitiza-
tion was associated with phosphorylation of the receptor but did not appear to be 
mediated by either a GRK or an effector kinase (Tobin et al. 1993; Tobin et al. 1996). It 
was subsequently found that this phosphorylation was mediated by casein kinase 1a 
(CK1a)(Tobin et al. 1997). The casein kinase 1 family is a group of ubiquitous 
serine/threonine protein kinases that recognize acidic residues in their substrates 
(Rowles et al. 1991). Although much is known about the biochemical properties of the 
four casein kinase 1 isoforms (a, p, y and 0) their physiological functions are largely 
undetermined (Mcinnes & Leader 1997). Indeed, 'casein kinase' is something of a mis-
nomer. While the enzyme is able to phosphorylate casein in vitro it is not the biological 
substrate for any of the enzymes (Tobin et al. 1997). In addition to the m3 muscarinic 
receptor CK1a has been shown to phosphorylate the m1 muscarinic receptor which, 
like the m3 receptor, undergoes a rapid desensitization following agonist exposure 
(Waugh et al. 1999). Initially it was thought that phosphorylation by CK1a might pro-
vide an alternative mechanism for desensitization of GPCRs (Tobin et al. 1997), but 
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subsequent research has suggested that it might be more important in regulation of the 
initial IP3 response following activation of these receptors (Budd et al. 2000). 
1.2.2 RECEPTOR SEQUESTRATION 
Following agonist-exposure many GPCRs are moved from the cell surface to an intra-
cellular compartment, most likely endosomes (von Zastrow & Kobilka 1992; Ferguson 
eta!. 1996b). Because they are inaccessible to both their hydrophilic ligands and G pro-
teins once internalized this process of receptor sequestration could contribute to 
desensitization (Sibley & Lefkowitz 1985). However, further investigation of the ~T 
adrenergic receptor system suggested that receptor internalization did not contribute to 
desensitization in normal circumstances. Firstly, blockade of receptor internalization 
using pharmacological agents such as hypertonic sucrose and concanavalin A (ConA) 
did not affect the ability of receptors to desensitize (Yu et a!. 1993; Pippig et al. 1995). 
Secondly, when compared with desensitization by receptor phosphorylation, receptor 
internalization was found to be relatively slow (t:n=10 min for the ~Tadrenergic recep-
tor [Roth et a!. 1991]) and as such sequestration would mostly affect already desensi-
tized receptors (Ferguson et a!. 1996b). Finally, receptor mutations which prevented 
receptor endocytosis had no effect on desensitization (Barak et al. 1994). Further inves-
tigation showed that rather than being a desensitizing process receptor internalization 
was important in resensitization, or recovery of responsiveness following desensitiza-
tion. Thus, pharmacological blockade of receptor internalization prevented resensitiza-
tion (Yu et a!. 1993; Pippig et al. 1995). Similarly, mutant ~Tadrenergic receptors 
which did not undergo endocytosis were not resensitized (Barak et al. 1994). 
These findings suggested that resensitization was dependent upon processing of 
the receptors which took place following internalization (B6hm et al. 1997). This pro-
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cessing may include dissociation of the ligand in acidified endosomes, dissociation of 
arrestins and dephosphorylation of the receptor by protein phosphatases which are 
associated with the endosomal compartment to which they are transferred (Bohm et al. 
1997). Dephosphorylation is dependent upon endosomal acidification, presumably 
because the low pH makes the phosphorylated receptor a substrate for protein phos-
phatases (Krueger et al. 1997). It is somewhat unclear which of the protein phos-
phatases is involved in this dephosphorylation, although both protein phosphatase 2A 
(PP2A)(Pitcher et al. 1995a) and protein phosphatase 2B (PP2B)(Shih & Malbon 
1996) have been implicated in dephosphorylation of the pz-adrenergic receptor. Fol-
lowing dephosphorylation the receptors are recycled back to the plasma membrane in a 
fully functional state (Pippig et al 1995). 
Similar models for the role of internalization in resensitization have been proposed 
for a number of GPCRs including the NKl neurokinin receptor (Garland et al. 1996), 
the o-opioid receptor (Hasbi et al. 2000) and the CB1 cannabinoid receptor (Hsieh et 
al 1999). However, in some instances the relationship between receptor internalization 
and desensitization and resensitization may not be so straightforward. Desensitization 
of the sst2B somatostatin receptor (Beaumont et al. 1998), the secretin receptor (Mun-
dell & Kelly 1998) and the V2 vasopressin receptor (Pfeiffer et al. 1998) can be inhib-
ited by pharmacological blockade of receptor internalization. Similarly, desensitization 
of the m2 muscarinic receptor can be prevented by pharmacological blockade of recep-
tor internalization when the receptor is expressed in Chinese hamster ovary (CHO) 
cells (Tsuga et al. 1998a), but when the receptor is expressed in HEK293 cells desensi-
tization is independent of internalization (Pals-Rylaarsdam et al. 1995; Pals-Rylaars-
dam & Hosey 1997). The reason for this difference in the pattern of desensitization in 
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these two cell types in unclear although Tsuga et al. (1998a) has suggested that it might 
be due to a lower level of receptor expression in the CHO cells. 
1.2.3 RECEPTOR DOWN-REGULA nON 
Desensitization can also be achieved through a decrease in the total number of recep-
tors, or down-regulation (Hausdorff et al. 1990). Compared with receptor desensitiza-
tion through uncoupling down-regulation is a slow process, requiring hours or days 
rather than seconds or minutes to take effect (Lohse 1993). Because resensitization 
requires the synthesis of new receptors it is similarly slow (B5hm et al. 1997). Down-
regulation can be achieved by either degradation of existing receptors (Bouvier et al. 
1989), or, alternatively, thrQugh a reduction in the rate of synthesis of new receptors 
(Hadcock & Malbon 1993). 
I.3 DESENSITIZATION OF THE ACTH RESPONSE TO AVP 
1.3.1 PREVIOUS STUDIES 
A variety of in vivo studies have shown that the HPA axis undergoes regulatory 
changes during chronic stress. A major component of this adaptation to stress is the 
regulation of CRH and AVP receptors in the pituitary (Aguilera 1994). Depending on 
the nature of the stress paradigm being employed, responsiveness to a novel stress can 
be either increased or decreased. Physical-psychological stress paradigms (such as 
repeated immobilization or ip hypertonic saline injection) are associated with hyper-
responsiveness to a novel stress whereas osmotic stress (such as 2% saline in drinking 
water or water deprivation) results in reduced pituitary ACTH responsiveness (Aguil-
era et al. 1994). In contrast to the CRH receptor, levels of which are either down-regu-
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lated or unchanged during adaptation of the HPA axis in response to chronic stress, 
there is a good correlation between changes in pituitary AVP receptor levels and pitu-
itary ACTH responsiveness (Aguilera 1994). During osmotic stress AVP binding in 
the rat pituitary is reduced whereas during physical-psychological stress AVP binding is 
increased. These changes in AVP receptor number are associated with changes in the 
biological effect of AVP at the pituitary: changes in AVP number correlate well with 
the ability of AVP to stimulate ACTH secretion from anterior pituitary cells isolated 
from control and experimental animals (Aguilera et al 1994). Together these results 
suggest that regulation of AVP receptors in the pituitary is a major determinant of cor-
ticotroph responsiveness during adaptation of the HPA axis (Aguilera 1994). In appar-
ent conflict with this hypothesis is the markedly increased ACTH secretion observed 
following adrenalectomy, despite decreases in pituitary AVP binding (Koch & Lutz-
Bucher 1985; Antoni et al 1985) and a reduced ability of AVP to stimulate IP3 forma-
tion in pituitaries from these rats (Todd & Lightman 1987). However, the high con-
centrations of ACTH observed are due to elevated basal secretion, and responses to 
stimulation are in fact decreased (Aguilera & Rabadan-Diehl 2000). 
Prolonged exposure to AVP results in homologous down-regulation of pituitary 
AVP receptors in vivo. Chronic injection of AVP into normal rats reduces pituitary 
AVP receptor levels by 80% (Antoni et al. 1985; Koch & Lutz-Bucher 1985). Similarly, 
in Bratdeboro rats, which are genetically deficient in AVP, chronic injection of AVP to 
a level which matches that of normal rats results in a reduction in receptor binding, 
indicating that physiological levels of AVP can also cause receptor down-regulation 
(Koch & Lutz-Bucher 1985). The decrease in pituitary AVP binding following 
adrenalectomy appears to be due, at least in part, to increased secretion of AVP from 
the hypothalamus following the removal of glucocorticoid negative feedback: surgical 
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lesioning of the paraventricular nucleus (a treatment which drastically reduces the 
number of AVP-secreting neurons in the hypothalamus [Karteszi et al. 1982]) reduces 
the extent of AVP receptor down-regulation (Antoni et al. 1985; Lutz-Bucher et al 
1986). However, in rats with hypothalamic lesioning cortisol replacement can com-
pletely prevent the loss of pituitary A VP receptors, indicating that glucocorticoids can 
directly regulate the pituitary AVP receptor (Lutz-Bucher et al. 1986). 
In vitro studies in the sheep, mouse and rat have shown that exposure of both pitu-
itary cells and segments to AVP results in desensitization of their ACTH response to a 
subsequent stimulation with AVP. When AVP was administered in 10 min pulses at 
60 min intervals to dispersed ovine anterior pituitary cells in a multi-column perifusion 
system there was a loss of responsiveness to the hormone with time (Evans et al. 1988). 
This loss of responsiveness was not appreciable at lower concentrations but at higher 
concentrations (between 100 and 2000 nM) the effect was marked. This reduction in 
response was not due to depletion of intracellular ACTH stores as desensitization to 
AVP did not reduce the response to CRH. Furthermore, cells stimulated continuously 
with sub maximal levels of A VP showed desensitization while ACTH was still available 
for release to higher levels of the hormone. Taken together these results indicated that a 
true desensitization process was involved. Desensitization of ACTH responsiveness has 
also been observed when either pituitary cells or segments are treated with AVP in 
static culture. Holmes et al. (1984) induced desensitization of the ACTH response to 
AVP in rat anterior pituitary segments by treating them with 100 nM AVP for 4 h. 
This treatment reduced the response to a subsequent 1 h stimulation with either 10 or 
1000 nM AVP by 27% and 60% respectively, while the response to CRH was 
unaffected. In parallel experiments binding of eHJ-Avp to pituitary membranes iso-
lated from rat anterior pituitary segments which had received a similar AVP treatment 
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was reduced by 71% (Antoni et ai. 1985). Murakami et al (1984) found that treatment 
of dispersed rat pituitary cells with 0.92 nM AVP for 6 h markedly reduced the ACTH 
response of cells to subsequent stimulation with AVP. When the AVP concentration of 
the pre-treatment was increased to 92 nM the response to subsequent A VP stimulation 
was abolished. Desensitization to AVP has also been observed in mouse anterior pitu-
itary cells (Castro 1993). Treatment with AVP at concentrations between 1 and 
100 nM for 3 h reduced the response to a subsequent 3 h stimulation with 100 nM 
AVP by up to approximately 50% (my calculation from Fig. 3B) without affecting the 
response to CRH. 
Although desensitization of the ACTH response to AVP can occur in vitro the 
mechanisms underlying this process are unknown. Phosphorylation of the pituitary 
AVP receptor has not been reported to date although the third intracellular loop and C 
terminal tail of the receptor contain phosphorylation consensus sequences for both 
PKC and the GRKs (Ventura et ai. 1999). Also, a green fluorescent protein(GFP)-
tagged Vlb receptor expressed in CHO cells has been shown to associate with PKCa. 
and with GRK5 (but not GRK2, GRK3 or GRK6) during agonist exposure (Berrada et 
ai. 2000). Receptor internalization may also play an important role in the regulation of 
the ACTH response to AVP since the pituitary AVP receptor has been shown to be 
internalized during AVP treatment (Mogensen et ai. 1988; Childs et ai. 1991; Berrada 
et ai. 2000). However, in these studies the relationship between internalization and 
ACTH responsiveness was not investigated. 
1.3.2 AIMS OF THIS STUDY 
The data described above show clearly that the pituitary AVP receptor is regulated dur-
ing adaptation to stress. Furthermore, this regulation plays a critical role in the control 
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of corticotroph responsiveness during the adaptation to chronic stress. Depending on 
the nature of the stressor, persistent or repeated stress can also result in reduction in 
pituitary AVP binding and ACTH responsiveness. While in vitro studies have shown 
that the ACTH response to AVP undergoes homologous desensitization following 
repeated or prolonged exposure to AVP this process is poorly characterized. In particu-
lar the relationship, if any, between the desensitization process seen in vitro and desen-
sitization, particularly adaptation to chronic stress, that occurs in vivo is unclear. 
Although the desensitization observed in vitro appears to be concentration-dependent 
it is unclear how quickly it occurs or if it can be reversed. Furthermore the AVP treat-
ment regimes used to induce desensitization in these studies do not match the condi-
tions to which corticotrophs are exposed in vivo. In the sheep, A VP secretion into the 
portal circulation is highly pulsatile, with secretory events rarely lasting more than 
30 min, and the AVP concentration rarely rising above 5 nM (Caraty et al. 1988; 
Engler et al. 1989; Caraty et al. 1990; Battaglia et al. 1998; Dadoun et al. 1998) whereas 
the studies described above used AVP treatments of supra-physiological concentration 
(>100 nM), very long duration (up to 4 h), or a combination of both. 
The first aim of this research was to characterize the desensitization of the ACTH 
response to AVP. Chapter 3 describes experiments in which the concentration- and 
dose-dependency of this process in ovine anterior pituitary cells were investigated using 
multi-column perifusion. Particular effort was made to ensure that the AVP treatments 
used to induce desensitization fell within the range of concentrations and durations of 
endogenous AVP pulses. As such, this study was aimed at investigation of the regula-
tion of ACTH responsiveness during acute rather than chronic stimulation with AVP. 
Additionally, the ability of cells to become resensitized following desensitization was 
investigated. 
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Both in vivo and in vitro studies have shown that regulation of the pituitary AVP 
receptor plays an important role in the regulation of corticotroph responsiveness. How-
ever the molecular mechanisms which are involved in the regulation of signalling via 
this receptor during acute stimulation are unknown. As described in Section 1.2, 
amongst the GPCR family desensitization can be mediated by either a reduction in 
total receptor number (i.e. down-regulation) or by preventing receptors from activating 
their signalling pathway. The latter mechanism is more rapid and is commonly 
achieved via receptor phosphorylation. Chapter 4 describes experiments in which the 
involvement of receptor phosphorylation in the desensitization of the ACTH response 
to AVP was investigated. Two approaches were taken. Firstly, the involvement of the 
intracellular protein kinasesPKC and CK1a in desensitization of the ACTH response 
to AVP of ovine anterior pituitary cells was investigated through the use of specific 
pharmacological inhibitors and activators of these enzymes. Secondly, the involvement 
of phosphorylation in regulation of the pituitary AVP receptor was investigated directly 
in experiments aimed at determining whether phosphate groups are incorporated into 
the receptor during A VP exposure. 
Receptor internalization also plays an important role in the regulation ofGPCRs, 
either by allowing resensitization of receptors or, in a few cases, causing desensitization 
because receptors are moved to a location where they are inaccessible to both their 
hydrophilic ligands and their associated G proteins. Although the Vlb receptor has 
been shown to internalize during AVP exposure the consequences of this are unknown. 
Chapter 5 describes experiments in which the role of receptor internalization in regula-
tion of the ACTH response to AVP was investigated by pharmacologically inhibiting 
receptor internalization. In many instances the role of internalization of GPCRs is to 
allow dephosphorylation of desensitized receptors by phosphoprotein phosphatases. 
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The involvement ofPP2A and PP2B, two phosphatases which have been implicated in 
the resensitization ofGPCRs (Pitcher eta!. 1995a; Shih & Malbon 1996), in the regu-
lation of the ACTH response to AVP was investigated using selective inhibitors of 
these enzymes. 
2.1 MATERIALS 
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For the sources of all materials used in this study, 
used were of analytical grade. 
2.2 SOLUTIONS AND MEDIA 
to Appendix A. All reagents 
For the details of all solutions and media used in this study, refer to Appendix B. 
2.3 CELL PREPARATION AND CULTURE 
2.3.I PITUITARIES 
Pituitaries were collected from freshly slaughtered, sexually mature (i.e. > 1 year old) 
female sheep (Ovis aires). Most often, whole heads were collected from either Alliance 
Group Ltd. (Sockburn, Christchurch) or the Malvern Abattoir Ltd. (Malvern, Canter-
bury) and transported on ice to the Department of Zoology, University of Canterbury. 
There the heads were cut posterio-anteriorally with a band saw, allowing the cut to pass 
just to the left of the pituitary gland, which was subsequently removed. On occasion, 
pituitary glands were collected from Canterbury Frozen Meats Ltd. (Belfast, 
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Christchurch). Because heads are routinely split at this plant it was possible to remove 
pituitary glands on site. Following their removal from the heads the pituitary glands 
(usually ten were collected) were placed in chilled, sterile dispersing buffer (DB; see 
Appendix B). Typically, no more than 45 min elapsed between slaughter of the animal 
and removal of the pituitary gland. 
2.3.2 PREPARATION OF DISPERSED OVINE ANTERIOR PITUITARY CELLS 
Chilled, sterile DB was used as the medium for preparation of dispersed ovine anterior 
pituitary cells. The cell preparation was performed in a laminar flow hood (CF43S, 
Gelman Sciences, Australia), and aseptic conditions were maintained throughout. All 
instruments and glassware used for' cell preparation had previously been either auto-
c1aved (15 min, 121°C, 15 psi), or heat sterilized (170°C, 2 h). Similarly, all plasticware 
and solutions used were sterile. 
The pituitary glands were washed by three brief submersions in fresh DB and then 
collected in DB on ice. Depending on their size, either seven or eight glands were 
selected to prepare the dispersed cells. Adhering connective tissue, the median emi-
nence, pituitary stalk and the posterior pituitary were removed. The anterior pituitaries 
were then rinsed once with DB and minced, with scissors, into pieces less than 2 mm3 
in size. Following mincing, the pituitary pieces were transferred to a trypsinizing flask 
containing 50 ml of collagenase solution (Type II collagenase [c1ostridiopeptidase A], 
480 U/ml DB). The flask was placed in a 3TC incubator and the tissue suspension was 
gently stirred with a magnetic stirrer. Cells were collected after an initial incubation 
period of20-30 min and again after two subsequent incubations of either 45 or 60 min 
duration. Generally the initial incubation produced few cells, but considerable connec-
tive tissue, and the tissue was discarded. Depending on the number of cells required 
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and the size of the pellets obtained from the second and third incubations, a fourth 
incubation, of 30 min duration, was occasionally required. Dispersed cells were col-
lected by decanting the supernatant from the trypsinizing flask and centrifuging this at 
200 x g (CR-412, Jouan, France) for 5 min at 4°C. The supernatant was returned to 
the trypsinizing flask for subsequent incubations while the cell pellet was washed by 
resuspending the cells in DB using a 10 ml pipette and centrifuging as before. 
The cells from the 1 h incubations were pooled and washed (as above) four times. 
After the third wash the cells were, if necessary, filtered through sterile U.S.P. Type VII 
gauze to remove any connective tissue and/or gelatinous material. Following the final 
wash the cells were resuspended in 25 to 40 ml of Dulbecco's modified Eagle's medium 
(DME; see Appendix B), supplemented with 10% new-born calf serum (NCS). A 
sample of this suspension was used to perform a cell count using a haemocytometer. 
Viability was determined by trypan blue exclusion (Dealtry 1992), and was typically 
greater than 85%, and never less than 80%. 
2.3.3 OVERNIGHT CULTURE OF CELLS 
For perifusion experiments, a cell suspension containing 4.5 x 106 viable cells/ml 
DMEINCS was prepared. Aliquots of this suspension (1 ml) were then transferred to 
plastic petrie dishes containing 19 ml ofDME/NCS. One plate was prepared for each 
of the perifusion columns, plus one for cell viability determination on the day of the 
perifusion. For the preparation of pituitary cell plasma membranes cells were cultured 
at a density of 20 x 106 viable cells per plate in 20 ml of DME/NCS. All cells were 
incubated overnight (approximately 18 h) at 370C in a 95% air:5% CO2 environment. 
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2.4 MULTI-COLUMN PERIFUSION EXPERIMENTS 
2.4.I PERIFUSION SYSTEM 
The multi-column perifusion system, as described previously and with modifications 
(McIntosh & McIntosh 1983, Evans et al. 1985, Evans et al. 1988, Evans et al. 1996), 
allows for the simultaneous perifusion of up to fifteen cell chambers, or columns. 
Through the use of a solenoid switching system various trains of AVP and pharmaco-
logical agents can be applied to the cells. The perifusion system is shown diagrammati-
cally in Fig. 2.1 and photographically in Fig. 2.2. 
Following overnight incubation, the cells from each cell culture plate were trans-
ferred in DME/NCS to separate 50 ml centrifuge tubes and pelleted by centrifugation 
at 275 x g for 5 min at 4°C (CR-412, Jouan, France). The supernatant was then aspi-
rated and replaced with 170 JlI of a slurry of Sephadex G-25 (fine) suspended at a ratio 
of 1:1.5 (vol:vol) in Krebs ringer (KR; see Appendix B), in preparation for transfer to 
the cell columns. Each of the cell columns has an internal volume of approximately 
500 Jll and is maintained at a temperature of 37"C by a tubular water jacket which 
encloses all fifteen columns. Before transfer of the cells to the columns, slurries of Bio-
Gel P-2 (80 Jll suspended 1:1.5 [vol/vol] in KR) and Sephadex G-25 (80 Jll suspended 
1:1.5 [vol/vol] in KR) beads were added to each of the columns to form a bead bed on 
which the cells would be supported. This bed was prevented from draining from the 
columns by a 10 JlID mesh Nybolt nylon gauze. The celllSephadex slurry was then 
placed onto this bead bed using a pasteur pipette, with care being taken to minimize 
disturbance of the cells. Each of the columns was then filled with KRI ATC (a KR solu-
tion containing 0.05% alkali-treated casein [ATC; prepared as described by Livesey & 
Donald [1982}] and 0.005% L-ascorbate) and sealed with a rubber bung into which the 
flow inlet tube was inserted. 
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Y junctions 
Fraction collector 
Solenoid switching 
system 
'Basal' 
'Test' 
Perifusion solutions 
Fig. 2.1. Diagram of the multi-column perifusion system. Arrow indicates direction of Row 
through the system. Note that while for clarity only three cell columns are shown here, in the 
actual system there are fifteen. 
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Fig. 2.2. Two views of the multi-column perifusion system showing the solenoid switching sys-
tem (1), Y junctions (2), peristaltic pump (3), cell columns enclosed in a tubular water jacket (4) 
and fraction collector (5). 
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Once cells had been transferred to each of the columns a multi-channel pump 
(Super Standby CPP15-30, ChemLab, England) was used to pump perifusion medium 
through fine tubing into the cell columns at a flow rate of 0.157 mVmin. The effluent 
from the columns was collected in 5 or 10 min fractions using a Gilson FC 204 fraction 
collector (Gilson, France). These samples were stored at-20°C and assayed for ACTH 
content by radioimmunoassay (RIA)(see Section 2.4.3). The different types and 
lengths of tubing used in the perifusion system are summarized in Fig. 2.3. 
During an experiment cells were perifused with a 'basal' solution (i.e. KRI ATC) 
and a 'test' solution containing AVP andlor various pharmacological agents. See 
Appendix B for details of the preparation of 'test' solutions. The tubing carrying these 
solutions was connected to the pump tubing by a Y-junction. At any given time one of 
these lines was clamped closed. Through the use of a solenoid-actuated switching sys-
tem the perifusion solution could be rapidly and precisely changed between the 'test' 
and 'basal' solutions. When the cells were perifused with 'basal' KRI ATC plus two sep-
arate 'test' solutions, the basal line was manually transferred between KRI ATC and the 
second 'test' solution. 
2.4.2 DESIGN AND ANALYSIS OF MULTI-COLUMN PERIFUSlON EXPERIMENTS 
2.4.2.1 EXPERIMENTAL DESIGN 
A variety of different experimental protocols were used in multi-column perifusion 
experiments. While the protocol used depended on the aim of the particular experi-
ment, the design and analysis of all experiments shared some common features. These 
are described below while the details of the specific treatment regimes used in individ-
ual experiments can be found in subsequent chapters. 
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PVC tubing 0,16 ml/min flow rated 
(Technicon) PVC pump tubing 
ID=0,02 in (Technicon/Elkay) 
ID=0,02 in 
7.5 em 40.6 em 
llil II 
Silastie laboratory tubing 
(Dow-Corning) 
ID=0.025In 
Mem 
Fig. 2.3. Types and lengths of tubing used in the multi-column perifusion system. The internal 
diameter (ID) of all tubing is indicated in inches. 
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Each of the fifteen columns in the perifusion system was randomly assigned an 
experimental treatment. Typically, each of the different treatments was repeated in at 
least two independent columns. In all experiments cells were perifused with 'basal' 
KRI ATC for at least 90 min at the beginning of the experiment, allowing them to 
recover from transfer into the columns. During this period ACTH secretion dropped 
to a consistently low level. The ability of a particular treatment to induce desensitiza-
tion was assessed by measuring its effect on a subsequent stimulation with 100 nM 
AVP for 5 min. The effect of this 'pre-treatment' on the subsequent 100 nM AVP 
'pulse' was assessed quantitatively by expressing the response to the AVP test pulse as a 
percentage of the response to similar pulses that had not been pre-treated (i.e. controls). 
2.4.2.2 DATA ANALYSIS 
ACTH responses to the pre-treatments and test pulses were calculated as follows from 
the raw data obtained from RIA. Firstly, the 'total ACTH secretion' during a period of 
stimulation was calculated from the ACTH concentration measured in the appropriate 
fractions using the equation: 
Total ACTH secretion (ng) l:{ [ACTH] in fraction X Fraction Duration X Flow rate } 
(ng/ml) (min) (mVmin) 
For the pre-treatment the 'total ACTH secretion' during the entire pre-treatment 
was calculated whereas for the test pulse 'total ACTH secretion' was calculated for a 
20 min period from the onset of the pulse. 
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The term 'response' refers to AVP-stimulated ACTH secretion. This was deter-
mined by subtracting basal ACTH secretion from the values calculated for 'total 
ACTH secretion', i.e.: 
A VP-stimulated ACTH secretion = Total ACTH secretion - Basal ACTH secretion 
Basal ACTH secretion was calculated using the mean ACTH secretion in the 
three fractions immediately preceding a pre-treatment or pulse. Where the fractions 
immediately preceding a pulse were collected during the pre-treatment, basal ACTH 
secretion was calculated using the fractions immediately prior to the pre-treatment. 
2.4.2.3 STATISTICAL ANALYSIS 
Data from perifusion experiments were statistically analyzed using a variety of software 
packages, namely Prism 3.0, Instat 1.0 (both from GraphPad Software, San Diego, 
CA) and Excel 8 (Microsoft, Redmond WA). Details of the different types of analyses 
used are indicated in the text. P<0.05 was considered significant. Actual levels of signi-
ficance are as indicated in the text. All data are reported as mean ± SEM. 
2.4.3 ACTH RADIOIMMUNOASSAY 
The ACTH concentration in perifusion samples was measured by direct RIA The pro-
cedures for the RIA of ovine ACTH (oACTH) have been described previously by 
Evans etal (1985). 
35 
METHODS 
2.4.3.1 TRACER 
1251-labelled oACTH (1251-oACTH) was prepared using a chloramine T radioiodina-
tion procedure (Hunter & Greenwood 1962). Briefly, 2.5 fig of highly purified 
oACTH (a kind gift from the late Dr C.H. Li; see Appendix A) was incubated with 
1251 in the presence of chloramine T for 1 min. At the end of this incubation the reac-
tion was stopped by the addition of sodium metabisulphite and the reaction mixture 
was separated from the labelled hormone either by elution from a cellulose column with 
horse plasma or by high performance liquid chromatography (HPLC). HPLC was car-
ried out on a reverse phase C8 column (300 A pore size; Brownlee RP300) with a ° to 
60% acetonitrile gradient. The tracer was aliquoted at volumes appropriate for use in 
the RIA and was stored frozen at -20'C for up to six weeks before use. 
Tracer purified on a cellulose column was repurified on the day of assay using the 
following procedure. 15 mg of silicic acid (100 mesh) was added to an aliquot of tracer 
and mixed by vortexing for 20 s. This was then centrifuged for 90 s at 1200 x g (bench-
top centrifuge, Griffen and George Ltd., England). The supernatant was discarded and 
the pellet was washed twice by resuspending it in 1 ml of distilled, deionized H20 
(ddH20) with vortexing followed by centrifugation as before. To elute the hormone 
from the silicic acid mesh 1 ml of an acetonelacetic acid solution (see Appendix B) was 
added, followed by vortexing and centrifugation. The supernatant containing the repu-
rified tracer was removed using a pasteur pipette and diluted in assay buffer (0.05 M 
phosphate buffer containing 0.1% ATC [P/ATC; see Appendix BJ) to 
10,000 cpmll00 Ill. Repurification ofHPLC-purified tracer was not necessary and this 
was diluted directly into PlATC. 
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2.4.3.2 ANTISERUM 
Antiserum, kindly provided by Professor Richard Donald (formerly of the Department 
of Endocrinology, Christchurch Hospital) was raised in rabbits by injection with two 
porcine ACTH preparations (ACTH with carboxymethylcellulose and ACTH zinc 
hydroxide). The antiserum was diluted 1:1400 in PI ATC for assay. 
2.4.3.3 ACTH STANDARDS 
A 100 gil oACTH (a gift from Dr C.H. Li; see Appendix A) solution was prepared by 
dissolving the dry powder in 0.003 M HCl. This was diluted in P/ATC to give a 
500 Ilg/1 stock solution. This stock solution was stored at -20nc in 1 ml aliquots. To 
prepare standards for use in RIA one of these aliquots was thawed and diluted with 
P/ATC to produce a stock solution of 10 Ilg/l oACTH. This was then diluted with 
appropriate volumes of PI ATC to produce standard solutions with the following con-
centrations: 10, 5, 3, 2, 1.5, 1, 0.5, and 0.25 Ilg/L Each standard was aliquoted into a 
mixture of 0.6 ml and 0.3 ml aliquots and stored at-20ne. P/ATC was used as the zero 
standard. 
2.4.3.4 REPLICATION STANDARDS 
Replicate samples of ACTH at three concentrations (high, ~3.0 Ilg/l; medium 
~1.3 Ilg/l; low ~0.4 Ilg/1) were included in each assay for quality control purposes. The 
inclusion of these samples at the beginning and end of each assay allowed assay preci-
sion to be monitored. Comparison of the ACTH concentration obtained for the repli-
cates was used to give an indication of the variation both within individual assays and 
between separate assays. The intra-assay co-efficients of variation for the high, medium 
and low ACTH replicates were 6.77%,9.25%, and 14.86% respectively. The inter-assay 
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co-efficients of variation for the high, medium and low ACTH replicates were 8.25%, 
19.29% and 15.42% respectively. 
Replicate standards were prepared as follows. Surplus cells from a cell preparation 
were incubated overnight in a 50 ml centrifuge tube. The next day the medium was 
changed and the cells were exposed to high concentrations of AVP and CRH for 2 h. 
The medium was collected after centrifugation and the pellet was resuspended in 
KRI ATC, vortexed vigorously and frozen and thawed to rupture the cells, releasing 
ACTH. The resulting suspension was centrifuged and the ACTH-containing superna-
tant was recovered and mixed with the supernatant from the fIrst centrifugation. 1 ml 
aliquots of these replicates were stored at -20T. 
2.4.3.5 ASSAY PROCEDURE 
Assays were set up in duplicate in an icelwater bath using the protocol described in 
Table 2.1. PIATC buffer, ACTH sample (either standard, experimental sample or rep-
licate), 125I-oACTH tracer and ACTH antiserum were added to the appropriate assay 
tubes in sequential fashion. Non-specific binding (NSB) tubes were included for each 
set of standards, replicate and set of samples. The concentration of ACTH in the 
experimental samples was such that dilution in the assay was generally not necessary. 
Once the addition of all reagents was complete the tubes were vortexed briefly (Multi-
tube Vortex, SMI, Miami FL) and incubated at 4°C for 18 to 20 h. 
2.4.3.1 ASSAY SEPARATION 
The antibody-bound 125I-oACTH was separated from the free labelled hormone by 
fractional precipitation, as follows. At the end of the incubation period, 50 III of either 
horse plasma or a 1.2% solution of bovine y-globulins in PI ATC was added to each 
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Table 2.1. Assay procedure for the RIA of oACTH. All volumes are in microlitres unless other-
wise indicated. 
Number Standard or sample Buffer sample r-globulin PEG serum 
2 o flg/I std 50 100 100 100 
3 o flg/l std jJ ,~ jJ ,~ 
4 0.25 flgll std 
5 0.5 flgll std 
6 1 flg/I std 
7 1.5 flg/l std 
8 2 flg/l std 
9 3 flgll std 
10 5 flg/l std 
11 10 flgll std 
12 Blank (assay zero) 250 100 
13 Assay zero 150 100 100 
14 Blank (High replicate) 150 100 100 () 
~ 
15 High replicate 50 100 100 100 "t;i 
16 Blank (medium replicate) 150 100 100 ~ 0 
'J:j 
17 Medium replicate 50 100 100 100 '" "§ 
Blank (low replicate) 150 100 u 18 100 .S 
19 Low replicate 50 100 100 100 ~ 
20 Blank (sam pIes) 150 100 100 'a .... ~ 
Samples (undiluted) 50 100 100 100 0 
JJ JJ JJ JJ JJ 
Blank (1,.2 dilution) 200 50 100 
Samples (Ih dilution) 100 50 100 100 
.~ jJ JJ JJ JJ 
Blank (High replicate) 150 100 100 
High replicate 50 100 100 100 
Blank (medium replicate) 150 100 100 
Medium replicate 50 100 100 100 
Blank (low replicate) 150 100 100 
Low replicate 50 100 100 100 
Blank (assay zero) 250 100 
Assay zero 150 100 100 
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tube, followed by 1.5 ml of an 18% polyethylene glycol solution (PEG; see Appendix 
B). After vigorous vortex mixing the tubes were incubated at room temperature for a 
total of 15 min. The antibody-bound hormone was then pelleted by centrifugation for 
15 min at 4,010 x g (Heraeus Varifuge 3.0R) at 4°C, and the supernatant was removed 
by vacuum aspiration. The radioactivity present was measured using a y scintillation 
counter (1275 Minigamma counter, LIrn Wallac) and the data obtained were stored as 
a computer file. 
2.4.3.2 ANALYSIS OF RIA OUTPUT 
The raw data (counts/2 min) were analyzed using the MRIAC RIA program (Livesey 
1974). The basis of this program is to fit a transformed standard curve by overlapping 
two or more straight line segments in order to achieve approximate linearity across the 
whole range of standards used. Each segment is as long as is consistent with linearity. 
The transformation used on the standards is related to the logit. The standard curve is 
then used to calculate the hormone concentration for each of the samples assayed. The 
value given by the program output is the mean for the duplicates, and a 95% confidence 
limit is set for each of the duplicates. 
2.5 PHOSPHORYLATION OF THE PITUITARY AVP RECEPTOR 
To investigate phosphorylation of the pituitary AVP receptor plasma membranes were 
isolated from both AVP-treated and control cells and retardation of the electrophoretic 
mobility of AVP receptors from these preparations was used as an indicator of phos-
phorylation. 
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2.5.1 PREPARATION OF PLASMA MEMBRANES 
Prior to preparation of plasma membranes, cells were treated with AVP to induce 
desensitization. Following overnight culture, 20 flM AVP stock solution was added to 
plates to give a final concentration of 50 nM. The medium was mixed by gently swirl-
ing the plates which were then incubated for a further 30 min at 37°C. A similar num-
ber of control plates, which were not treated with A VP, were also prepared. To ascertain 
whether this treatment was capable of inducing desensitization 1 ml aliquots from 
treated and untreated plates were transferred to sterile culture tubes, centrifuged at 
625 )( g for 10 min at 4°C (CR-412, Jouan), and the supernatant was replaced with 
either DME/NCS or DME/NCS containing 100 nM AVE After a 90 min incubation 
the tubes were centrifuged again. Following centrifugation an aliquot of the superna-
tant was removed and its ACTH concentration was determined by RIA. It was found 
that the ACTH response in cells pre-treated with 50 nM AVP was reduced by 
41.0 ± 5.5%. 
Following treatment with 50 nM AVP for 30 min the cells were transferred in 
DMEINCS from the culture plates to 50 ml centrifuge tubes and recovered by centri-
fugation at 625 )( g for 10 min at 4"C (CR-412, Jouan). After aspiration of the super-
natant the cells were resuspended in 4 ml ofice-cold inhibitor buffer (IE; see Appendix 
B). This cell suspension was then transferred to a 15 ml Dounce homogenizer 
(Wheaton, Millville NJ) and homogenized with fifteen passes of a tight fitting pestle. 
One homogenizer was used for all cells from control plates and a second was used for 
all cells from A VP-treated plates. The homogenates were then centrifuged at low speed 
(1,049)( g; Varifuge 3.0R, Heraeus) to remove undamaged cells, partially ruptured 
cells, and nuclei. The resulting supernatant was centrifuged at 50,000 x g (RC-
M150GX, Sorvall), and the sealed tubes were then sliced open using a hot scalpel 
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blade. The supernatant was aspirated and the plasma membrane-containing pellets 
were resuspended in 400 fl.l of protein assay buffer (PAB; see Appendix B). A small ali-
quot (~25 fl.l) was removed for protein assay and the remainder was frozen in liquid 
nitrogen and stored at _20DC. The protein concentration of the membrane fraction was 
determined using a bincinchonic acid protein assay (BCA Protein Assay Kit, Pierce, 
Rockford IL). Each culture plate of 20 x 106 cells yielded approximately 200 fl.g of 
membrane protein. 
2.5.2 CROSS-LINKING a}' 125I_AVP TO THE PITUITARY AVP RECEPTOR 
Sufficient membrane preparation to give 100 fl.g of protein was transferred to micro-
tubes and centrifuged at 20,800 x g 30 min (5417, Eppendorf Hamburg, Ger-
many). The supernatant was aspirated and the pellet resuspended in PAE. This 
membrane preparation was incubated with NO.25 nM (3-[125I]iodotyrosyl2)Vaso-
pressin[Arg8] (125I-AVP) for 2 h either alone or in the presence of 2.5 fl.M unlabelled 
A VP according to the protocol shown in Table 2.2. 
Table 2.2. Incubation of pituitary cell membrane preparations with 
125I-AVP. 
Membrane protein 
PAB 
~2.5 nM 125I_AVP 
(final concentration -0.25 nM) 
25 f11\1 AVP 
(final concentration 2.5 f1M) 
Total 
NSB Experimental 
100 f1g 
200 f1l 
25 f1l 
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After incubation for two hours at room temperature lOA fll of a 25 mM solution 
of the cross linker disuccinimidyl suberate (DSS) in dimethylsulfoxide (DMSO) was 
added to give a final concentration of 1 mM. The incubation was then continued for a 
further 20 min before 250 flll M Tris'HCI (pH 7.5) was added to stop the reaction. 
2.5.3 ELECTROPHORESIS OF MEMBRANE PREPARATIONS 
Following cross-linking, the membrane proteins were separated by sodium dodecyl sul-
phate polyacrylamide gel electrophoresis (SDS-PAGE) and the labelled bands were 
visualized by autoradiography. The cross-linked membrane preparations were centri-
fuged at 20,800 x g for 30 min (5417, Eppendorf), the supernatant aspirated, and the 
pellets resuspended in 20-30 f1l of SDS-PAGE sample buffer (commercially prepared 
2)( concentrate [4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol 
blue, 0.125 M Tris'HCI, pH ~6.8; Sigma Chemical Co., St Louis MO] diluted in 
PAB). The samples were then placed in a boiling water bath for 3 min, before separa-
tion on unidirectional polyacrylamide slab gels prepared according to the method of 
Laemmli (1970). Details of the preparation of gels can be found in Appendix B. Best 
separation was achieved using 24 cm long, 1.5 mm thick, 12% polyacrylamide gels 
(with a 4% stacking gel) run at 20 A constant voltage. Molecular weight markers 
(SigmaMarkers) were electrophoresed alongside the samples. Gels were stained over-
night in a Brilliant Blue G-TCA solution (prepared as described by Blakesley & Boezi 
[1977]) and destained in ddH20 for a further 24 h. Gels were dried at 60°C for 2 h 
(Model 543, Biorad Laboratories, Hercules CA). Dried gels were apposed to XAR-5 
film (Eastman Kodak, Rochester NY) with X-Omatic intensifying screens (Eastman 
Kodak, Rochester NY) for 2 weeks at -70·C. 
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CHARACTERISTICS OF THE DESENSITIZATION OF 
THE ACTH RESPONSE TO AVP 
3.1 INTRODUCTION 
In vivo studies have shown that the pituitary AVP receptor undergoes regulatory 
changes during adaptation to chronic stress (Aguilera 1994; Aguilera & Rabadan-
Diehl 2000). Similarly, a number of in vitro studies have shown that anterior pituitary 
cells become desensitized following prolonged or repeated exposure to AVP (Holmes et 
al1984; Evans et al. 1988; Castro 1993). The AVP treatments used to induce desensi-
tization in these in vitro experiments were either of long duration, high concentration 
or a combination of both. For example, Holmes et al. (1984) observed desensitization 
of the ACTH response to AVP in dispersed rat anterior pituitary cells following treat-
ment with 100 nM AVP for 4 h (see Section 1.3.1 for a more extensive discussion). 
In contrast to these AVP treatment regimes the secretion of AVP into the hypo-
physeal portal circulation is highly pulsatile with peak concentrations of relatively low 
magnitude. In the sheep, sampling of the hypophyseal portal blood has been possible in 
unrestrained and conscious animals. Using this technique it has been shown that pulsa-
tile AVP secretion into the portal blood is stimulated by a variety of stressors including 
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insulin-induced hypoglycaemia (Engler et al 1989; Caraty et al. 1990), audiovisual 
stress (Engler et al. 1989); haemorrhagic stress (Caraty et al. 1988) and endotoxin infu-
sion (Battaglia et al 1998; Dadoun et al 1998). In all of these studies basal AVP secre-
tion rates were very low, with exposure to a stressor resulting in peaks of AVP secretion. 
There was a high degree ofinter-anirnal variation, but the maximal AVP concentration 
in the portal plasma following exposure to a stressor ranged from approximately 1 nM 
for acute haemorrhage (Caraty et al. 1988), to ~6 nM for insulin-induced hypoglycemia 
(Caraty et al 1990) and ~4 nM for endotoxin exposure (Battaglia et al. 1998). Assess-
ment of the duration of endogenous AVP pulses and the inter-pulse period is some-
what more problematic. In the studies described above a 10 min sampling period was 
used. At this sampling frequency it is difficult to estimate the duration of endogenous 
pulses with great precision (Alexander et al. 1994; Gudmundsson & Carnes 1997), 
although it appears that in most cases secretory events rarely last more than about 
30 min and occur approximately once an hour. In the horse a unique venous pathway 
exists which allows pituitary venous blood to be collected as soon as it leaves the pitu-
itary (Alexander et al. 1994). Because of the large size of horses, samples can be taken 
more frequently than is possible in the sheep. Using this technique, with a 5 min sam-
ple period, Redekopp et al. (1986) found that pulses of AVP were surprisingly brief, 
usually less than 10 min in duration, and frequent, occurring at 15 to 25 min intervals. 
It is unclear whether the desensitization of the ACTH response to A VP which has 
been shown to occur in vitro takes place under conditions that are characteristic of AVP 
pulses in vivo. The aim of the following experiments was to determine whether desen-
sitization occurs in vitro in response to AVP pulses that are similar in magnitude and 
duration to those measured in the hypophyseal portal blood. Also, the time required for 
resensitization to occur was investigated. 
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The rapidity with which desensitization and resensitization occur may give some 
clues as to the mechanisms involved in the desensitization process. Amongst the 
GPCR family desensitization can be achieved by either a reduction in total receptor 
number (down-regulation) or by preventing receptors from activating their signalling 
pathway (uncoupling), which is commonly mediated by phosphorylation of the recep-
tor by intracellular protein kinases. Alternatively, uncoupling can be achieved by mov-
ing receptors to an intracellular location where they are inaccessible to both their 
hydrophilic ligands and G proteins. Compared with down-regulation, which takes 
place over a period of hours or days, uncoupling is rapid, occurring within seconds or 
minutes of the onset of the stimulus. Furthermore, because it does not require the syn-
thesis of new receptors, the effects of uncoupling are much more readily reversed than 
those of down-regulation (Lohse 1993). 
3.2 RESULTS 
3.2..1 DESENSITIZATION OF THE ACTH RESPONSE TO AVP 
The first series of experiments was designed to determine the concentrations and dura-
tions of AVP treatment which cause desensitization. The experimental protocol for 
these experiments was based on that used by Weiss et al. (1995) to investigate desensiti-
zation of gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone 
secretion. In this procedure cells are repeatedly stimulated with short pulses of a 
secretagogue at a high concentration. In order to induce desensitization one of these 
pulses is preceded by a treatment with a lower concentration of the secretagogue. The 
extent of desensitization is assessed quantitatively by expressing the response to this 
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pre-treated pulse as a percentage of the response to the other pulses, which act as con-
trols. 
Using the multi-column perifusion system (see Section 2.4), dispersed ovine ante-
rior pituitary cells were stimulated with 5 min pulses of 100 nM AVP after 100, 180 
and 260 min of perifusion. This resulted in three similar peaks of ACTH secretion 
(Fig. 3.1a). When the response to the second pulse was expressed as a percentage of the 
mean of the responses to the first and third pulses no significant difference could be 
found (n=6, not significant [NS], Student's t-test). Therefore, when the second pulse 
was preceded by a desensitizing A VP pre-treatment the first and third pulses were used 
as controls. Pre-treatment of the second 100 nM AVP pulse for 25 min with 5 nM 
AVP reduced the response by 37.9 ± 3.7% (n=7, P<O.OOOl, t-test) compared to the con-
trols (Fig. 3.1b). This pre-treatment had no effect on the response to the third 100 nM 
AVP pulse: the response to this pulse was unchanged following pre-treatment of the 
second pulse compared to the response observed in the absence of pre-treatment. 
It can be seen from Fig. 3.1a that there was a small reduction in response from one 
100 nM AVP pulse to the next. The responses to the second and third pulses were 
found to be reduced by 10.7 ± 5.2% (n=6, NS, t-test) and 22.2 ± 2.1% (n=6, P<O.OOO1, 
t-test) compared to the first pulse. This reduction in response did not appear to be due 
to specific (i.e. receptor-mediated) desensitization processes since a similar reduction in 
response from one pulse to the next was also observed when cells were stimulated with 
5 min pulses of 50 mM KCl in place of 100 nM AVP, although these reductions in 
response were not found to be statistically significant (Fig. 3.2a). Response to the sec-
ond and third 50 mM KCl pulses dropped by 6.7 ± 3.5% (n=3, NS, t-test) and 
16.1 ± 4.5% (n=3, NS, t-test). KCl does not activate a cell surface receptor and stimu-
lates ACTH secretion by directly depolarizing cells (Old et al. 1990). Also, when cells 
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Fig. 3.1. Desensitization of the ACTH response to AVP. Representative data from three inde-
pendent columns of the perifusion system illustrating the experimental protocol used in these 
experiments are shown. Cells were treated with 5 min pulses of 100 nM AVP after 100, 180 
and 260 min of perifusion (indicated by arrows). To induce desensitization the second pulse was 
preceded by a pre-treatment with 10 nM AVP for 25 min (indicated by the black bar). In the 
column shown in (c) the cells were treated with a single 100 nM pulse after 260 min of perifu-
SlOn. 
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Fig. 3.2. Effect of treatment with KCl on ACTH secretion. Cells were treated with 5 min 
pulses of 50 mM KCl after 100, 180 and 260 min of perifusion (indicated by arrows). Pre-treat-
ment of the second KCl pulse with 5 nM AVP for 25 min (indicated by black bar) resulted in an 
increase in ACTH secretion compared to the control pulses. Representative data from two 
indepedent perifusion columns are shown. 
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were treated with a single 100 nM A VP pulse after 260 min of perifusion, the response 
to this pulse was not significantly different to the response to a 100 nM AVP pulse at 
100 min (Fig. 3.1c). Together these data suggest that the reduction in response from 
one pulse to the next was not the result of a true desensitization but was due to non-
specific processes, probably depletion of intracellular ACTH stores. 
In contrast, the reduction in response to AVP following pre-treatment with AVP 
seen in Fig. 3.1b reflected a specific desensitization of the cells to AVP. This was dem-
onstrated by replacing the three AVP pulses with 5 min pulses with 50 mM KCL Fol-
lowing pre-treatment with 5 nM AVP for 25 min prior to the second pulse it was found 
that there was no reduction in the response to the second KCl pulse compared to the 
responses to the control pulses (Fig.> 3.2b). In fact, there was a significant increase in 
ACTH secretion in response to the KCl pulse following AVP pre-treatment (ACTH 
secretion increased to 198.8 ± 18.4% of control, n=3, P<0.05, t-test). This is consistent 
with a report by Le Beau & Mason (1998) who found that AVP and KCI were syner-
gistic at low concentrations. Also, pre-treatment with 300 ~ l,2-dioctanoyl-sn-glyc-
erol (DiC8), a specific PKC activator and ACTH secretagogue (Watanabe & Orth 
1988; Won et al 1995), did not reduce the response to a subsequent stimulation with 
100 nM AVP, indicating that stimulation of ACTH secretion was not, in itself, suffi-
cient to induce a reduction in response to a subsequent stimulation with 100 nM AVP 
(see Section 4.2.1 for details). Overall, these results clearly show that the reduction in 
response to an AVP pulse following pre-treatment is the result of an AVP-specific 
desensitization process. 
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3.2.2 EFFECT OF CONCENTRATION OF AVP PRE-TREATMENT ON DESENSITIZATION 
To investigate the concentration-dependency of desensitization, the duration of the 
pre-treatment was held constant at 25 min while the AVP pre-treatment concentration 
applied to different columns was varied from 0.1 to 50 nM. Representative results from 
five perifusion columns are shown in Fig. 3.3 and the combined data are summarized in 
Fig. 3.4. AVP pre-treatment desensitized the response to a subsequent AVP pulse in a 
concentration-dependent manner. A sigmoidal concentration-response curve was fitted 
to the data yielding an r2 of 0.93 and a predicted value for 50% desensitization (IC 50) 
of the ACTH response of 6.54 nM AVP The lowest concentration of AVP tested 
which was capable of causing a significant reduction in response was 2.0 nM (n=3, 
P<0.02, t-test). The ACTH release following pre-treatment with 50 nM AVP was 
maintained at a plateau by the second AVP pulse, rather than the pulse causing a 
response peak as seen at lower pre-treatment concentrations. 
3.2.3 EFFECT OF DURATION OF AVP PRE-TREATMENT ON DESENSITIZATION 
The degree of desensitization of the response to an AVP pulse was also found to be 
dependent on the duration of the pre-treatment. A similar protocol to that described 
above was used except that the concentration of the pre-treatment was held constant at 
5 nM while the duration varied from 0 to 25 min. Data from five independent perifu-
sion columns are shown in Fig. 3.5, while the combined data are summarized in 
Fig. 3.6. A pre-treatment for as little as 5 min resulted in a significant reduction 
(21.5 ± 1.5% of control, n=3, P<0.005, t-test) in the response to the second AVP pulse 
compared to the mean of the responses to the first and third pulses. A greater reduction 
in the response to the second AVP pulse (39.4 ± 8.6%, n=3, P<0.05, t-test) was 
observed when the duration of the 5 nM AVP pre-treatment was increased to 10 min. 
51 
CHARACTERISTICS OF THE DESENSITIZATION OF THE ACTH RESPONSE TO AVP 
5 
a 
:;J4 
'" as 
~2 
'- \.. L 
100 180 260 
Il!l!!:!l 
b t t t 
;J4 
'" a3 
~2 ~ 
..... ~ \....... \.. 0 
100 180 260 
5 t t c ~4 
"" '  a3 
~2 
100 180 26() 
d 
:;J4 
'" as 
~2 
0 
100 180 280 
5 
e 
~4 
"" '  a3 
L 
~ 
100 180 26() 
Time (mn) 
Fig. 3.3. Effect of pre-treatment concentration on desensitization of the ACTH respone to 
AVP. Representative data from five independent perifusion columns are shown. The second 
AVP pulse was pre-treated with AVP at the concentration indicated for 25 min. 
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Fig. 3.4. Concentration-dependence of the desensitization of the ACTH response to AVP, 
determined using the experimental protocol shown in Fig. 3.3. The ACTH response to the sec-
ond AVP pulse was expressed as a percentage of the control pulses. The concentrations used for 
the 25 min pre-treatment are plotted on a log scale. Data are mean ± SEM (n=2-7 for each 
treatment). 
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Fig. 3.5. Effect of pre-treatment duration on desensitization of the ACTH response to AVP. 
The concentration of AVP in the pre-treatment was held constant while the duration was var-
ied. Pre-treatment durations were a) 5 min; b) 10 min; c) 15 min; d) 20 min and e) 25 min. 
Representative data from five independent perifusion columns are shown. 
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Fig. 3.6. Time-dependence of the desensitization of the ACTH reponse to AVP. The ACTH 
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duration of the AVP pre-treatment. The concentration of AVP used for the pre-treatment was 
5 nM. Data are mean ± SEM (n=3-7 for each treatment). 
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However, extending the pre-treatment period beyond 10 min did not result in any fur-
ther increase in the magnitude of desensitization. 
3.2.4 RESENSlTIZATION OF THE ACTH RESPONSE TO AVP 
Perifused anterior pituitary cells were clearly quite sensitive to desensitization of the 
ACTH response to AVP. To characterize this process further, the ability of desensitized 
cells to recover their responsiveness to AVP was investigated. Since it was anticipated 
that the effects of desensitization would take somewhat longer to be reversed than they 
did to occur, an experimental protocol different to that used to investigate the time-
and concentration-dependency of desensitization was employed. Cells were stimulated 
with a single 5 min pulse of 100 nM- AVP after 200 min of perifusion. This pulse was 
preceded by a 15 min pre-treatment with 10 nM AVP. Unlike the experimental proto-
col used in the first series of experiments the cells were allowed a recovery period of up 
to 80 min between the pre-treatment and the AVP pulse. During this recovery period 
they were perifused with medium alone. In order to quantitatively assess the extent of 
resensitization, the response of the pre-treated cells to 100 nM AVP was expressed as a 
percentage of the mean response of the control cells (i. e. cells that had not been pre-
treated) to a 100 nM AVP pulse. 
Data from five independent perifusion columns are shown in Fig. 3.7. Combined 
data are summarized in Fig. 3.8. When the AVP pulse was applied immediately upon 
termination of the pre-treatment (i.e. 0 min recovery time) the magnitude of the 
response to the test pulse was reduced to 36.7 ± 5.4% (n=7, P<O.Ol, One way ANOVA 
with Dunnett's test) of the response observed in controls that were not pre-treated. 
When the cells were allowed a 10 min recovery period between the pre-treatment and 
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Fig. 3.7. Recovery of the ACTH response to AVP following desensitization. Cells were treated 
with a single 100 nM AVPpulse after 200 min of perifusion (indicated by arrows). Pre-treat-
ment with 10 nM A VP for 15 min decreased the response to the AVP pulse (b) compared to the 
control (a). When a recovery period was allowed between the pre-treatment and the pulse the 
response to the pulse increased. Durations of the recovery periods shown above were c )2 Omin; 
d) 40 min; e) 80 min. Representative data from five independent perifusion columns are shown. 
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Fig. 3.8. Time-course of resensitization of the ACTH response to AVP. The ACTH response 
after pre-treatment with 10 nM AVP for 15 min is plotted against the duration of the recovery 
period (i.e. the period of time betweeen the pre-treatment and the AVP pulse during which the 
cells were perifused with medium alone). Data are mean ± SEM (n= 7-15 for each treatment). 
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the test pulse there was a partial recovery in response to 67.3 ± 7.6% (n=8, P<O.Ol, 
Dunnett's test) of control. Recovery was complete after 40 min. 
3.3 DISCUSSION 
This study shows that desensitization of the ACTH response of cultured ovine anterior 
pituitary cells to AVP occurs more rapidly and at lower AVP concentrations than has 
previously been reported. Previous in vitro studies have shown that desensitization to 
AVP following stimulation with AVP at either high concentrations or for long periods 
of time (Holmes etal. 1984; Antoni et al 1985; Evans et al. 1988; Castro 1993). These 
experimental treatments contrast with the endogenous pattern of AVP secretion into 
the hypophyseal portal circulation which is highly pulsatile, with the AVP concentra-
tion of pulses normally being less than 5 nM (Engler et al. 1989; Caraty et al 1990; 
Engler etal. 1989; Caraty etal. 1988; Battaglia etal. 1998; Dadoun et al1998). 
Using an experimental protocol based on that described by Weiss et al. (1995) I 
have investigated desensitization of the ACTH response to AVP pulses at concentra-
tions and durations which more closely match those of endogenous pulses. Using this 
experimental paradigm it was found that pre-treatment with A VP at concentrations as 
low as 2 nM was capable of eliciting a significant reduction in response to a subsequent 
100 nM AVP pulse. The ICso for this desensitization process was calculated to be 
6.54 nM. Furthermore it was found that the desensitization was rapid, with the maxi-
mal desensitization to 5 nM AVP being reached after 10 min of pre-treatment. The 
resensitization of the ACTH response was also investigated and it was found that the 
response returned to a level not significantly different to that of the controls after a 
recovery period of 40 min. 
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The comparison of these results with the results of studies which examined the 
endogenous AVP pulse characteristics is interesting. As indicated above, in the sheep, 
peak concentrations of AVP in the hypophyseal portal blood during stress are less than 
6 nM and secretory events appear to last no more than about 30 min. Taken together, 
these data suggest that while most endogenous AVP pulses would be long enough to 
cause desensitization their low concentrations would elicit only partial desensitization. 
This raises the question of whether this type of rapid desensitization plays a role in nor-
mal physiology. Weiss et al (1995) investigated the desensitization of perifused pitui-
tary cells to GnRH and found a qualitatively similar relationship between in vitro 
desensitization and endogenous pulse characteristics: endogenous GnRH pulses would 
have been long enough, although not of great enough concentration to evoke desensiti-
zation. It was suggested that the role of desensitization was not to prevent gonadotro-
pin secretion, but rather to limit the maximum secretory response to GnRH. It is 
possible that desensitization to AVP plays a similar role in the regulation of ACTH 
secretion. If this were the case, it would suggest that corticotrophs have an intrinsic 
set-point, beyond which they become refractory to further stimulation with AVP. Fur-
thermore, the rapidity of the desensitization of the ACTH response to AVP might act 
to limit the duration of secretory episodes. Together these two properties of the desens-
itization process could result in a stereotyping of ACTH pulse amplitude and duration 
(Leng & Brown 1997). 
The characteristics of the desensitization which has been observed give some clues 
to the mechanisms which may underlie it. As described above, amongst the G protein-
coupled receptors there are two types of mechanism which result in desensitization: 
those which affect the ability of receptors to activate their signalling pathways (uncou-
pling) and those that result from a reduction in total receptor number (down-regula-
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tion)(Lohse 1993). Uncoupling of receptors from their signalling pathways is rapid, 
occurring within seconds or minutes of the stimulus onset (Roth et al. 1991), and is 
readily reversible (Lohse 1993). In contrast, down-regulation is a relatively slow pro-
cess, requiring hours to take effect (Hausdorff et al. 1990). Furthermore, because it 
involves degradation of existing receptors (Hausdorff et al. 1990) or the inhibition of 
the production of new receptors (Hadcock & Malbon 1993) it is relatively slow to 
reverse. The speed with which desensitization of the ACTH response to AVP occurs 
and its rapid resensitization strongly suggest that the mechanism(s) underlying it 
involve uncoupling of the receptor from its signaling pathway. Commonly uncoupling 
is mediated by receptor phosphorylation which, either directly or indirectly, prevents 
receptors from interacting with their associated G proteins (Grady et al. 1997). Desens-
itization of both the V1a (Innamorati et al. 1998a) and V2 (Innamorati et al. 1997) 
AVP receptors is mediated by receptor phosphorylation, and it is possible that desensi-
tization of the V1b receptor is mediated in a similar manner, although the involvement 
of other mechanisms (such as receptor sequestration) cannot be excluded. 
The rapid resensitization of the ACTH response to AVP suggests that this rapid 
desensitization is more likely to be involved in regulating the acute response to AVP 
rather than altering the responsiveness of the corticotroph to chronic stress. The 
changes in AVP receptor number and associated changes in corticotroph responsiveness 
observed by Aguilera et al. (1994) following exposure to various chronic stress para-
digms are most likely the result of a down-regulation process rather than the rapid 
desensitization observed here. 
The regulation of ACTH secretion is a complex process which is influenced not 
only by the independent action of stimulatory factors (such as CRH and AVP) and 
inhibitory factors (such as glucocorticoids) but also by complex interactions of these 
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factors with one another (Evans et al 1996). It is possible that some of these factors are 
capable of modulating the degree of desensitization of pituitary cells to AVP. In the 
sheep, since ACTH secretion is dependent upon the co-ordinated action of AVP and 
CRH, it is important to consider the effect of CRH on the desensitization of the 
ACTH response to AVP. Using an experimental protocol similar to that described 
above, it has been shown that this desensitization is unaffected by treatment with CRH 
(Chacko 2000; Chacko et al. 2000). Presence of a low concentration of CRH 
(0.01 nM) during perifusion neither prevented nor enhanced the desensitization of the 
ACTH response to AVP. It remains possible that other factors, such as glucocorticoids, 
may modulate the desensitization process, thereby providing an additional level of con-
trol of ACTH secretion. 
In summary, it has been shown that the ACTH response toA VP undergoes rapid 
desensitization. The concentrations and durations of AVP exposure which are capable 
of eliciting desensitization suggest that this desensitization process may play an impor-
tant physiological role in the regulation of ACTH secretion from the anterior pituitary. 
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ROLE OF PROTEIN KINASES IN THE 
DESENSITIZATION OF THE ACTH RESPONSE TO AVP 
4.1 INTRODUCTION 
The results of the experiments described in the previous chapter show that the ACTH 
response to AVP of perifused dispersed ovine anterior pituitary cells is rapidly and 
reversibly desensitized. These characteristics of the desensitization suggest that the 
molecular mechanisms underlying it involve uncoupling of the pituitary AVP receptor 
from its signalling pathway. This is a common mechanism of rapid desensitization 
amongst the GPCR family and is most commonly mediated by phosphorylation of the 
receptor on serine and/or threonine residues by one or more protein kinases (Lohse 
1993). A variety of different protein kinases are capable of phosphorylating GPCRs. 
These include the GRK family (Premont et at. 1995), the effector kinases PKA and 
PKC (Pitcher et al. 1992) and CK1a (Tobin et at. 1997). The aim of the following 
research was to investigate the involvement of receptor phosphorylation in desensitiza-
tion of the ACTH response to AVP. In particular, the involvement ofPKC and CK1a 
in the desensitization process was investigated. 
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The A VP receptor expressed in the anterior pituitary is of the Vlb subtype (J ard et 
al 1986; Sugimoto et al 1994).lt shares a relatively high degree of homology (45.5%) 
with the Via AVP receptor and both are coupled to the phosphoinositide signalling 
pathway (De Keyzer et aI. 1994). Like the V1b receptor, signalling through the Via 
receptor undergoes desensitization following exposure to AVP (Cantau et aI. 1988; 
Grier et aI. 1989; Caramelo et aI. 1991; Gallo-Payet et al 1991; Nathanson et al 1994; 
Ancellin et aI. 1997). This desensitization process is both concentration -dependent and 
rapid, with significant desensitization occurring within 30 s of AVP exposure in vascu-
lar smooth muscle cells (Carame1o et aI. 1991). Evidence suggests that desensitization 
of the V1a receptor is mediated, at least in part, by PKC-mediated phosphorylation. 
Firstly, desensitization of signalling through the Via receptor can be induced by acti-
vating PKC. Both pre-treatment with specific PKC activators such as 1,2-dicotanoyl-
sn-glycerol (DiCs), 1-oleoyl-2-acetyl-sn-glycerol (OAG), phorbol-12-myristate-13-
acetate (PMA) and phorbol-12,13-dibutyrate (PDBu)(Gallo-Payet et al 1991; Ance1-
lin et al 1997; Ancellin & More11998), and direct injection of the catalytic subunit of 
PKC into cells (Ancellin et aI. 1997) cause a reduction in response to a subsequent 
stimulation with AVP. (Note that Nathanson et al [1994] did not observe significant 
desensitization of the Via receptor following treatment with PDBu. This was probably 
because a PDBu treatment of insufficient duration was used to induce desensitization 
[Ancellin & Morel 1998]). Secondly, desensitization can be significantly reversed by 
down-regulation of PKC by 24 h treatment with PMA (Caramelo et aI. 1991). Finally, 
an increase in phosphorylation of the Via receptor has been observed following treat-
ment with PMA (Innamorati et al 1998a) and activation of the PLC-coupled m3 mus-
carinic receptor (Ancellin et aI. 1999), indicating that PKC is able to phosphorylate the 
receptor. 
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Given that there are structural similarities between the Via and Vlb receptors and 
that the two receptors have similar signalling properties it is possible that the molecular 
mechanisms involved in their desensitization are also similar. Consistent with this 
hypothesis, Berrada et al (2000) have shown that during agonist exposure PKCa inter-
acts with a GFP-tagged Vlb receptor expressed in CHO cells. Alternatively, the mech-
anism involved may be different. It has been proposed that such differential 
desensitization may explain the existence of receptor subtypes with otherwise similar 
pharmacological and signalling properties (Kurose & Lefkowitz 1994; Nantel et al. 
1993). I have used two approaches to investigate the involvement of PKC in desensiti-
zation of the ACTH response to AVP. Firstly, the ability of the specific PKC activator 
DiCs to induce desensitization of the ACTH response to AVP was assessed. Secondly, 
the effect of inhibition ofPKC on AVP-induced desensitization was investigated using 
the highly selective PKC inhibitor Ro 31-8220. 
the specific PKC activator DiCs to induce desensitization of the ACTH response 
to AVP was assessed. Secondly, the effect of inhibition of PKC on AVP-induced 
desensitization was investigated using the highly selective PKC inhibitor Ro 31-8220. 
G RKs have been found to be involved in the regulation of some PLC-coupled 
GPCRs, including the alB-adrenergic receptor (Diviani et al. 1996), the AT lA angio-
tensin II receptor (Oppermann et al. 1996) and the substance Preceptor (Kwatra et al. 
1993). However, changes in the intracellular environment following activation ofPLC 
appear somewhat unfavourable to activation of G RKs. Following activation of PLC 
levels ofPIP2 in the plasma membrane fall by up to 80% (Willars et al. 1996; Wilson et 
al 1985; Koreh & Monaco 1986). PIP2 plays an important role in the regulation of 
GRK activity: a synergistic interaction between PIP2, G~"1 subunits and the pleckstrin 
homology domain in the C-terminus of GRK2 promotes translocation of the enzyme 
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to the plasma membrane, thereby enhancing its ability to phosphorylate agonist-occu-
pied receptors (Pitcher et al. 1995b; DebBurman et al. 1996). Similarly, PIP2 regulates 
membrane association of GRK4, GRKS and GRK6, although in this instance this is 
the result of interactions of the phospholipid with the NHTterminus of the enzymes 
(Pitcher et al. 1996). Furthermore, the rise in intracellular Ca2+ which follows activa-
tion of PLC-coupled receptors may also discourage the activity of G RKs: translocation 
ofGRK2 and GRK3 to the plasma membrane is inhibited by the ability ofCa2+/cal-
modulin to compete for the binding of G~'Y subunits (Chuang et al 1996; Haga et al. 
1997) and GRK5 translocation is inhibited by a direct interaction of Ca2+ !calmodulin 
with the kinase (Chuang et al 1996). The inhibitory effect of Ca2+ Icalmodulin on 
GRK2 activity only occurs at relatively high calmodulin concentrations (ICso ~2 flM) 
suggesting that it might only be physiologically important in tissues such as brain 
where calmodulin levels are high (Pitcher et al. 1998). Finally, PKC-mediated phos-
phorylation has been shown to inhibit G RK5 (Pronin & Benovic 1997), although, on 
the other hand, it has also been shown to activate GRK2 (Chuang et al. 1995; Winstel 
et al. 1996). 
Since these conditions may be unfavourable for activity of the GRKs, particularly 
GRK5, it has been suggested that in some cases alternative mechanisms might be 
involved in the regulation of PLC-coupled GPCRs. Recently it has been shown that 
CK1a phosphorylates the PLC-coupled m3 muscarinic receptor (Tobin et al. 1997). 
This phosphorylation was agonist-dependent and was associated with a rapid desensiti-
zation of the cellular responses to stimulation. Subsequently it has been shown that 
CK1a can also phosphorylate rhodopsin (Tobin et al 1997) and the m1 muscarinic 
receptor (Waugh et al 1999), suggesting that it may have a broad substrate specificity 
amongst the GPCRs. Interestingly, two yeast casein kinase 1 homologues, Yck1p and 
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Yck2p, have been shown to phosphorylate a GPCR, namely the a pheromone receptor 
ste2p (Hicke et al. 1998). Although it was originally suggested that CKla-mediated 
phosphorylation might provide an alternative mechanism for desensitization of PLC-
coupled receptors, replacing G RKs in some instances (Tobin et al. 1997), more recent 
evidence suggests that CKla-mediated phosphorylation may not mediate desensitiza-
tion of the m3 muscarinic receptor but is instead involved in the regulation of the initial 
IP3 response to stimulation. Expression of a catalytically inactive mutant CKla was 
found to have no effect on desensitization but resulted in an increase in the initial IP 3 
response. Excision of the third intracellular loop, which contains the residues 
phosphorylated by CKla, had a similar effect on the IP3 response. These changes in 
response may have reflected enhanced coupling of the receptor to G q/ll (Budd et al. 
2000). 
As the Vlb receptor is coupled to PLC the involvement ofCKla in the regulation 
of signalling through this receptor was investigated. This was achieved using the 
specific casein kinase 1 inhibitor CKl-7. The effect of treatment with this agent on 
both the ability of AVP pre-treatment to induce desensitization and its effect on the 
initial ACTH response to AVP were investigated. 
While the experiments described above were designed to investigate the involve-
ment of specific protein kinases in the desensitization of the ACTH response to AVP 
they do not show directly whether the effects of these protein kinases are mediated by 
phosphorylation of the receptor. Like the Via and V2 AVP receptors (both of which 
are phosphorylated following agonist exposure [Innamorati et al. 1997; Innamorati et 
al. 1998a; Ance1lin et al. 1999]) the V1b receptor contains a number of serine residues 
in its intracellular loops and C terminal tail that are potential sites for phosphorylation 
(De Keyzer et al. 1994; Ventura et al. 1999). In light of this, phosphorylation of the 
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pituitary AVP receptor during agonist-exposure was investigated directly. Stadel et al. 
(1983) showed that desensitized ~-adrenergic receptors migrated more slowly on poly-
acrylamide gels than receptors isolated from control cells. This retarded mobility was 
due to the incorporation of phosphate groups into the receptor. A similar approach was 
used to investigate the phosphorylation of the Vlb receptor, with the receptor being 
visualized on polyacrylamide gels by the cross-linking of a radiolabelled ligand. 
4.2 RESULTS 
4.Z.1 EFFECT OF PRE-TREATMENT WITH I,Z-DIOCTANOYL-SN-GLYCEROL ON THE 
ACTH RESPONSE TO AVP 
In order to investigate the involvement of PKC In desensitization of the ACTH 
response to AVP the effect of pre-treatment with DiCs on a subsequent stimulation 
with AVP was assessed. DiCs is a synthetic diacylglycerol that strongly activates PKC 
(Go et al. 1989), and as such treatment with this agent results in a marked stimulation 
of ACTH secretion from anterior pituitary cells (Watanabe & Orth 1988; Won et al. 
1995). IfPKC were involved in the desensitization process one would expect that pre-
treatment with DiCs would reduce the response to a subsequent stimulation with A VP. 
Experiments were carried out using the multi-column perifusion system (see Sec-
tion 2.4). The experimental design and analysis used were essentially similar to those 
used to investigate the desensitization of the ACTH response to A VP and are 
described in detail in Section 3.2.1. Briefly, cells were stimulated with 5 min pulses of 
100 nM AVP after 100, 180 and 260 min of perifusion resulting in three similar peaks 
of ACTH secretion (Fig. 4.1a). The second pulse was preceded by either a 15 min pre-
treatment with 10 nM AVP (Fig. 4.1b) or a 15 min pre-treatment with DiCs at con-
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Fig. 4.1. Effect of pre-treatment with DiCs on the ACTH response to AVP. Data in each panel 
are from single, representative columns in which prior to the second 100 nM AVP pulse the 
cells received either no pre-treatment (a)i or a 15 min pre-treatment with 10 nM AVP (black 
bar; b); 30 ~ DiCs (open bar; c); 100 pM DiCs (d); 300 ~ DiCs (e). AVP pulses are indi-
cated by arrows. 
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centrations of either 30, 100 or 300 ~ (Fig. 4.1c, d, e). The effect of this pre-treat-
ment on the ACTH response to AVP was assessed quantitatively by expressing the 
response to the second pulse as a percentage of the response to the first and third pulses. 
Secretion of ACTH during pre-treatment with DiCs was concentration-depen-
dent (Fig. 4.2). Treatment with 30 fIM DiC s caused a small but significant increase in 
ACTH secretion above basal (n=6, P<O.Ol, Student's t-test). When the concentration 
was increased to 300 fIM, stimulated ACTH secretion was not significantly different 
from that observed during pre-treatment with 10 nM AVP (One way ANOVA with 
Dunnett's test). 
Despite stimulating ACTH secretion at a level equivalent to AVP, pre-treatment 
with DiCs did not induce desensitization. In contrast to pre-treatment with 10 nM 
Avp, which caused a reduction in response of 48.6 ± 1.6% (n=6, P<O.OOOl, Student's t-
test) to a subsequent stimulation with Avp, the ACTH response to AVP was increased 
in a concentration-dependent manner following pre-treatment with DiCs (Fig. 4.3). 
While pre-treatment with 30 fIM DiCs had no significant effect on the response to the 
subsequent 100 nM AVP pulse, pre-treatment with 100 11M DiCs caused a 9.9 ± 3.7% 
(n=6, P<0.05, t-test) increase compared with controls, and after a 300 fIM DiCs pre-
treatment the response was increased by 51.3 ± 4.4% (n=6, P<O.OOO1, t-test). 
4.2.2 EFFECT OF PRE-TREATMENT WITH RO 31-8220 ON DESENSITIZATION OF THE 
ACTH RESPONSE TO A VP 
The involvement of PKC in the desensitization of the ACTH response to AVP was 
investigated further using Ro 31-8220. Ro 31-8220 (or, more fully, 2-[1-[3-(amidino-
thio )propylJ-1H-indol-3-yl}-3-(1-methylindol-3-yl)-maleimide methanesulfonate), is 
a potent, selective inhibitor ofPKC derived from the bacterial metabolite staurosporine 
ROLE OF PROTEIN KINASES IN THE DESENSITIZATION OF THE ACTH RESPONSE TO AVP 
ns 
10 nM AVP 30 I-IM DiCS 100 I-IM DiCS 300 I-IM DiCS 
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Fig. 4.2. Effect of treatment with DiC8 for 15 min on ACTH secretion. Treatment with DiC8 
caused significant increases in ACTH secretion above basal at all concentrations tested. DiC8-
stimulated ACTH secretion was concentration-dependent, with treatment with 300 11M DiC8 
causing ACTH secretion equivalent to that stimulated by 10 nM AVP (Dunnett's test). Data 
are mean ± SEM (n=6 for each treatment). 
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Fig. 4.3. Effect of pre-treatment with DiCS on the ACTH response to a subsequent stimula-
tion with AVP. The data shown are the responses, expressed as a percentage of control, to a 
5 min, 100 nM AVP pulse following pre-treatment for 15 min with the indicated solutions. 
Data are mean ± SEM (n=5-6 for each treatment). Asterisks indicate a statistically significant 
difference between the results observed and 100% (t-test, * P<0.05, *** P<O.OOl). 
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(Davis et al. 1992). It was provided as a kind gift by Dr G. Lawton of the Roche 
Research Centre, We1vvyn Garden City, UK. Ro 31-8220 was used to inhibit PKC 
activity during treatment with AVE If PKC were involved in the desensitization pro-
cess then treatment with Ro 31-8220 would be expected to impair the ability of an 
AVP pre-treatment to induce desensitization of the ACTH response to a subsequent 
stimulation with AVP. 
Again, experiments were carried out using the multi-column perifusion system 
with an experimental design similar to that described in Section 3.2.1. To induce 
desensitization the second 100 nM AVP pulse was preceded by a 15 min pre-treatment 
with 10 nM AVP. In initial experiments the effect of PKC inhibition of the develop-
ment of this desensitization was assessed by treating the cells with 2 flM Ro 31-8220 
for a short period (20 min) prior to the second AVP pulse. This experimental design 
was similar to that used to investigate the involvement of CKl a in desensitization (see 
Section 4.2.3). Unfortunately it was found that the effects of treatment with 
Ro 31-8220 were not confined to the second AVP pulse: the response to the third 
100 nM AVP pulse was significantly reduced by a prior treatment with Ro 31-8220 
alone. Because of these long-lasting effects of treatment with Ro 31-8220 it was not 
possible to use the first and third pulses as controls. In an attempt to avoid this problem 
it was decided to treat cells with Ro 31-8220 at a constant 'background' concentration 
for the duration of the experiment. Treatment with 2 flM Ro 31-8220 began at 90 min 
and continued throughout the experiment until its completion (i.e. 300 min). This 
treatment with Ro 31-8220 reduced the ACTH response to each of the 100 nM AVP 
pulses. This effect was not uniform however, with the reduction in response being more 
marked for the second and third pulses. As a result the response to the second AVP 
pulse was 28.8 ± 8.4% less than the mean of the response to the first and third pulses in 
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the absence of AVP pre-treatment. Although this reduction was not significant 
(P=0.0749, n=3, t-test) it was decided that it was not appropriate to use this method of 
analysis to assess the extent of desensitization induced by AVP pre-treatment. Instead, 
the response to the second AVP pulse following pre-treatment was compared to the 
response to the second AVP pulse in control columns which received no pre-treatment. 
This analysis was performed both when 2 flM Ro 31-8220 was present in the perifu-
sion medium and when it was absent. During treatment with 2 flM Ro 31-8220 the 
ACTH response to the 100 nM AVP was reduced by 45.1 ± 3.5% (n=7, P<O.OOO1, t-
test) compared to controls which were not treated with Ro 31-8220. Despite being able 
to inhibit ACTH secretion, treatment with Ro 31-8220 did not reduce the extent of 
desensitization observed. Following- pre-treatment with AVP in combination with 
2 flM Ro 31-8220 the response to a subsequent stimulation with 100 nM AVP was 
reduced by 88.8 ± 4.5% (n=4, P<O.Ol, t-test) compared to the corresponding control 
(Fig. 4.4a, b). In contrast, following AVP pre-treatment in the absence ofRo 31-8220 
the response to a 100 nM AVP pulse was reduced by 69.8 ± 2.4% (n=3, P<0.05, t-
test)(Fig. 4.4c, d). This difference in the magnitude of reduction in response caused by 
AVP pre-treatment was significant. (n=7, P<0.05, t-test). Results are summarized in 
Fig. 4.5. 
4.2.3 EFFECT OF PRE-TREATMENT WITH CKI-7 ON DESENSITIZATION OF THE ACTH 
RESPONSE TO AVP 
The role of CKla in the regulation of AVP-stimulated ACTH secretion was investi-
gated using the potent casein kinase 1 inhibitor CKl-7 (N-(2-aminoethyl)-5-chloro-
isoquinoline-8-sulfonamide). This cell-permeable isoquinoline sulfonamide compound 
is a highly selective inhibitor of casein kinase I activity (IC50=9.5 flM), with a much 
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Fig. 4.4. Effect of treatment with Ro 31-8220 on desensitization of the ACTH response to 
AVP. Treatment with a 100 nM AVP pulse (indicated by arrows) resulted in a peak of ACTH 
secretion both in the presence (a) and absence (c) of 2 f1M Ro 31-8220. Pre-treatment with 
10 nM AVP for 15 min (indicated by black bars) resulted in a reduction in response to a subse-
quent stimulation with 100 nM AVP, both in the presence (b) and absence (d) of 2 flM 
Ro 31-8220. Representative data from four independent perifusion columns are shown. 
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weaker effect on casein kinase II and other protein kinases (Chijiwa et al 1989). The 
involvement of CKlo: in desensitization of the ACTH response to AVP was investi-
gated by testing the effect of treatment with CKl-7 on the ability of AVP pre-treat-
ment to induce desensitization. If CKlo: were involved in desensitization then the 
presence ofCKl-7 would be expected to reduce the extent of desensitization induced 
by AVP pre-treatment. 
Once again, experiments were carried out using the multi-column perifusion sys-
tem with an experimental protocol similar to that described in Section 3.2.1. Pre-treat-
ment of the cells for 25 min with 10 nM AVP prior to the second 100 nM AVP pulse 
caused a reduction in response of 49.0 ± 3.1% (n=9, P<O.OOl, t-test)(Fig.4.6a) com-
pared with controls. To investigate the involvement ofCKlo: in desensitization the sec-
ond 100 nM AVP pulse was immediately preceded by a 30 min treatment with CKl-7 
at concentrations of 30, 100 or 300 11M (i.e. for 5 min before the pre-treatment and 
then concurrendy with it for 25 min)(Fig. 4.6b, c, d). Treatment with CKl-7 at all 
three concentrations had no effect on AVP-induced desensitization, with the reduction 
in response induced by AVP pre-treatment not being affected by any of these concen-
trations of CKl-7 (Dunnett's test). In order to assess the effect of treatment with 
CKl-7 alone on the response to a subsequent AVP stimulation, the second pulse was 
preceded by a pre-treatment with 30 11M CKl-7 for 30 min. Following this pre-treat-
ment the response to the second AVP pulse was not significantly altered compared to 
the controls (n=6, NS, t-test)(Fig. 4.6e). Results are summarized in Fig. 4.7. 
Treatment with CKl-7 both alone and in combination with AVP had no effect on 
ACTH secretion. During pre-treatment with 30 11M CKl-7 alone ACTH secretion 
was not significandy increased above basal (n=6, NS, t-test). Similarly, treatment with 
10 nM AVP in combination with CKl-7 had no effect on stimulated ACTH secretion 
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Fig. 4.6. Effect of pre-treatment with CKla on desensitization of the ACTH response to AVP. 
Data in each panel are from single, representative perifusion columns in which the second 
100 nM AVP pulse has been preceded by a treatment with either 30 11M CKl-7 for 30 min (a); 
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(e). Black bars indicate the 10 nM AVP pre-treatment, open bars indicate CKl-7 treatment 
and arrows indicate 100 nM AVP pulses. 
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during the 25 min 10 nM AVP pre-treatment. (NS, Dunnett's test). Results are sum-
marized in Fig. 4.8. 
4.2.4 PHOSPHORYLATION OF THE PITUITARY AVP RECEPTOR 
Cell culture of dispersed ovine anterior pituitary cells was performed as described in 
Section 2.3.3. Treatment of these cells with AVP, preparation of plasma membranes, 
cross-linking of 1251_AVP to these membrane preparations and SDS-PAGE were car-
ried out as described in Section 2.5. When samples of plasma membrane preparation 
containing 100 flg of protein were electrophoresed without incubation with, or cross-
linking to, 1251_AVP a satisfactory separation of proteins on the gel was achieved. 
Staining with Brilliant Blue G-TCA 'solution showed that many distinct protein bands 
were present within the 46 to 76 kD range expected to be occupied by the pituitary 
AVP receptor (The human Vlb receptor is a 424 amino acid protein with a predicted 
molecular weight of 47 kD [De Keyzer et al. 1994J. The rat VIa receptor is a 424 
amino acid protein [1nnamorati et al. 1996J with a predicted molecular weight of 
46 kD, but migrates between 62 and 76 kD on SDS-PAGE, with the diffurence proba-
bly attributable to receptor glycosylation [1nnamorati etal1998aJ). When these mem-
brane preparations were incubated with 1251_AVP and cross-linked to the radiolabelled 
ligand with DSS there was a marked change in the banding pattern observed. 
Although discrete bands had previously been clearly visible they were now no longer 
distinct. Autoradiography showed that 1251_AVP had bound and been cross-linked to 
proteins in the membrane preparation. However, binding of 1251 -AVP to these proteins 
appeared to be non -specific as it was not affected by the presence of an excess of 'cold' 
AVP. No difference in the pattern of 1251_AVP binding to membranes from control and 
AVP-treated cells could be observed. 
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Fig. 4.8. Effect of treatment with CKl-7 on AVP-stimulated ACTH secretion. Black bar indi-
cates a 25 min treatment with 10 nM AVp, beginning at 155 min of perifusion. The response of 
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ment. Data are mean ± SEM (n=9 for each treatment). 
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4.3 DISCUSSION 
The results described above show that PKC does not mediate the desensitization of the 
ACTH response to AVE Indeed, the data suggest that rather than acting as a feedback 
mechanism, activation of PKC primes the phosphoinositide signalling pathway, 
thereby increasing the response to subsequent stimulation. 
Despite being able to potently activate PKC, treatment with DiC8 was not capable 
of inducing desensitization. During the 15 min pre-treatment 300 11M DiC8 stimu-
lated ACTH secretion equivalent to that stimulated by pre-treatment with 10 nM 
AVE However, in contrast to the marked desensitization observed following 10 nM 
AVP pre-treatment, pre-treatment with DiCs did not reduce the response to a subse-
quent stimulation with 100 nM AVP. In fact, the opposite was true, with DiCs pre-
treatment markedly increasing the response to a subsequent stimulation with 100 nM 
AVE While the data presented here give no clue as to which PKC substrates are 
responsible for this increase in AVP-stimulated ACTH secretion, a possible explana-
tion is provided by previous studies of the role of PKC in the regulation of C a2+ influx 
into corticotrophs. The ACTH response to AVP is dependent to a large extent upon 
the entry of extracellular Ca2+ through L-VSCC (Abou-Samra et al. 1987; Won et al. 
1990; Corcuff et al. 1993; Le Beau & Mason 1994). In many tissues the activity of 
L-VSCC is modulated by phosphorylation of the channels by a variety of protein 
kinases (see McDonald 1994 for review). Depending on the tissue being studied the 
effects of PKC on Ca2+ entry can be either positive (e.g. smooth and skeletal muscle 
[Navarro 1987; Fish et al. 1988J) or negative (e.g. sensory neurons [Rane & Dunlap 
1986]). In human ACTH-secreting pituitary adenoma cells AVP enhances Ca2+ entry 
through L-VSCC (Mollard et al. 1988). This suggests that some factor activated by 
AVP, possibly PKC, modulates the activity of L-VSCC in corticotrophs. In dispersed 
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ovine anterior pituitary cells there is a synergistic interaction between low concentra-
tions of AVP and raised extracellular K+ on ACTH secretion (Le Beau & Mason 
1998). This synergistic interaction was dependent upon PKC activity and it has been 
suggested that it might have been the result of modulation of L-VSCC activity by PKC 
resulting in increased Ca2+ entry, and thus increased ACTH secretion. Such a modula-
tion ofL-VSCC activity by PKC could explain the increase in AVP-stimulated ACTH 
secretion following treatment with DiCs. Activation of PKC by DiCs could increase 
the activity of L-VSCC, resulting in an increase in Ca2+ entry during the subsequent 
100 nM AVP pulse. This would, in turn, result in increased ACTH secretion. While 
such a mechanism could explain the results which have been observed in this study 
other mechanisms cannot be excluded. PKC phosphorylates a number of cytosolic (Liu 
et al. 1994) and membrane (Liu 1994) proteins in ovine anterior pituitary cells. Any of 
these PKC substrates might be responsible, either direcdy or indirectly, for the increase 
in AVP-stimulated ACTH secretion following DiCs treatment which has been 
observed in this study. 
Since activation ofPKC plays a critical role in mediating AVP-stimulated ACTH 
secretion (Abou-Samra et al 1986; Carvallo & Aguilera 1989; Liu et al. 1990), it was 
not surprising that treatment with the specific PKC inhibitor Ro 31-8220 markedly 
inhibited the ACTH response to AVP. However, effects of Ro 31-8220 treatment on 
ACTH secretion made it somewhat difficult to devise an experimental protocol which 
allowed a meaningful assessment of the effect of PKC inhibition on the ability of AVP 
pre-treatment to induce desensitization. Specifically, treatment with 2 ~ 
Ro 31-8220, either for a short period prior to the second A VP pulse or as a background 
throughout the experiment, affected the relationship between the AVP pulses. Because 
of this it was not possible to assess the effect of pre-treatment on the second pulse by 
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using the first and third pulses as controls for the second. A partial solution to this 
problem was to express the response to a 100 nM AVP pulse following pre-treatment 
as a percentage of the mean response to similar, but unpre-treated control pulses. When 
analyzed in this way the results were not consistent with the hypothesis that PKC 
mediates the desensitization of the ACTH response to AVP. As indicated above, treat-
ment with 2 11M Ro 31-8220 reduced AVP-stimulated ACTH secretion: the response 
to the second 100 nM AVP pulse was reduced by 45.1% by Ro 31-8220 treatment. 
This reduction in response indicates that treatment with Ro 31-8220 at this concentra-
tion was capable of inhibiting PKC activity. Despite its ability to inhibit PKC the pres-
ence of Ro 31-8220 did not reduce the extent of desensitization induced by 15 min 
pre-treatment with 10 nM AVP. Indeed, when expressed as a percentage of the appro-
priate control, the reduction in response induced by AVP pre-treatment was actually 
greater when Ro 31-8220 was present in the perifusion medium than when it was 
absent. It seems highly unlikely this could be the result of reduced phosphorylation of 
the Vlb receptor by PKC. There is no evidence in the literature to suggest that a reduc-
tion in PKC-mediated phosphorylation of a GPCR can enhance its desensitization. 
Recent evidence has shown that when stably transfected in CHO cells a GFP-tagged 
human Vlb receptor associates with GRK5 (but not with GRK2, GRK3 or GRK6) 
during agonist exposure, although it was not demonstrated whether the receptor 
becomes phosphorylated during this interaction (Berrada et al. 2000). One possible 
explanation for the increased reduction in response observed during treatment with 
Ro 31-8220, is that inhibition of GRK5 by PKC-mediated phosphorylation was 
reduced, thereby resulting in enhanced phosphorylation and desensitization of the 
receptor. However, given that the intracellular environment following activation of 
PLC is very unfavourable to activation of GRK5 (see above) it would be surprising if 
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this enzyme were involved in the desensitization of the ACTH response to AVP. The 
interaction between the GFP-tagged V1b receptor and GRK5 may have been an arte-
fact of expression of the receptor in the CHO cells. A more plausible explanation is 
that this effect is the reverse side of the increase in responsiveness to AVP observed fol-
lowing treatment with DiCs. In this instance treatment with 2 flM Ro 31-8220 
reduces the extent ofPKC activation during the 10 nM AVP pre-treatment. As a result 
PKC-mediated 'priming' of the signalling pathway during the AVP pre-treatment is 
reduced and subsequent stimulation with 100 nM A VP is less effective. 
Receptor phosphorylation by the effector kinases is an heterologous mechanism of 
desensitization and agonist-occupancy of receptors is not obligatory for their 
phosphorylation and desensitization (Lohse 1993). However there is a small increase in 
the rate of phosphorylation of the ~-adrenergic receptor by PKA in vitro when the 
receptor is isoproterenol bound (Benovic et al. 1985). Use of Ro 31-8220 to inhibit 
PKC allowed the role of this enzyme in desensitization to be investigated while the 
receptor was AVP-bound, which was not possible in experiments in which DiCs was 
used to activate PKC. The results obtained do not support the involvement of PKC in 
desensitization of the pituitary AVP receptor, even when agonist-bound. 
No evidence could be found for the involvement of CK1a in the regulation of 
AVP-stimulated ACTH secretion. Casein kinase 1 activity was inhibited using the 
specific inhibitor CK1-7 at three concentrations, all of which were greater than the 
ICso for this inhibitor measured in a cell-free enzyme system (Chijiwa et al. 1989). 
Treatment with CK1-7 had no effect on the magnitude of desensitization induced by a 
25 min pre-treatment with 10 nM AVP, nor did it have any effect on basal and AVP-
stimulated ACTH secretion. 
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Attempts to biochemically determine whether the pituitary AVP receptor is phos-
phorylated during desensitization were unsuccessful. Non-specific binding and cross-
linking of the radiolabelled ligand to proteins present in the membrane preparation 
made it impossible to determine whether the electrophoretic mobility of the receptor 
had been altered. 
The lack of involvement ofPKC in desensitization of the ACTH response to AVP 
suggests AVP receptor subtype-specific differences in mechanisms of desensitization: 
the Via vasopressin receptor, which is expressed largely in the liver and vasculature 
(Watson & Arkinstall 1994), has been shown to be desensitized via PKC-mediated 
receptor phosphorylation (Gallo-Payet et al. 1991; Ancellin et al. 1997; Ancellin & 
Morel 1998; Caramelo et al. 1991). -Differential desensitization of the Via and Vlb 
receptors might explain, at least in part, the existence of two receptors with otherwise 
similar signalling properties. These differences in desensitization might play an impor-
tant role in the regulation of responsiveness to AVP in different tissues. It is interesting 
to note that the patterns and maximal concentrations of AVP secretion into the pitu-
itary portal circulation are quite different from those in the peripheral circulation. AVP 
is released into the portal blood in a highly pulsatile manner and reaches relatively high 
concentrations, e.g. up to ~6 nM during insulin-induced hypoglycaemia in sheep (Car-
aty et al. 1990; see Section 3.1 for a more extensive discussion). In contrast, changes in 
AVP concentration in the peripheral circulation are slow and oflow magnitude, e.g. fol-
lowing hypertonic saline infusion into ewes there is a steady increase in plasma AVP 
concentration from ~2 pM to ~7 pM over a period of 90 min (Keller-Wood 1994). 
Since GRK-mediated desensitization of the ~-adrenergic receptor is very rapid 
(t1h<15 s) and requires relatively high agonist concentrations it has been suggested that 
this process might be particularly important in environments such as the synaptic cleft 
86 
ROLE OF PROTEIN KINASES IN THE DESENSITIZATION OF THE ACTH RESPONSE TO AVP 
where agonist concentrations Increase rapidly to high concentrations (1-
100 flM)(Lohse et al 1990a; Roth et al. 1991). Correspondingly, the desensitization of 
the ~-adrenergic receptor mediated by the PKA is slower (t1;2=3.5 min) and occurs at 
lower agonist concentrations, suggesting that it is better suited to the regulation of 
responsiveness at non-synaptic receptors (Roth et al. 1991). Differences in the mecha-
nisms underlying the desensitization of the Via and Vlb receptors could allow appro-
priate regulation of the responsiveness to AVP to occur in the different tissues in which 
the two receptors are expressed. 
While neither PKC nor CKla appear to be involved in the desensitization of the 
ACTH response to AVP it remains likely that an intracellular protein kinase is involved 
in this process. Perhaps the best remaining candidates for phosphorylation of the Vlb 
receptor are members of the GRK family. Using immunocytochemistry for GRK2, 
GRK3, GRK6 and ~-arrestins Neill et al. (1998) showed that these proteins are 
expressed in rat anterior pituitary cells, indicating that the intracellular machinery nec-
essary for the regulation of the Vlb receptor by GRKs is present in pituitary cells. Fur-
thermore, as described above, recent evidence has shown that the Vlb receptor can 
interact with GRKs (Berrada et al 2000). For a number of reasons the investigation of 
the involvement of GRKs in the desensitization of the ACTH response to AVP is 
somewhat difficult. Although a number of substances, including heparin (Lohse et a!. 
1989), Zn2+ (Benovic et a!. 1987b) and the wasp venom peptide mastoparan (Tang et 
a!. 1998), have been reported to modulate GRK activity, each has non-specific effects. 
Heparin also inhibits casein kinase 2 (Hathaway et al. 1980) and is an IP3 receptor 
antagonist (Kobayashi et al. 1989), Zn2+ reduces cell viability (Hasbi et al. 1998), while 
mastoparan activates Go and G i (Higashijima etal 1988; Tanaka eta!' 1998). Further-
more, neither heparin nor mastoparan are cell permeable and cells must be permea-
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bilized in order for these compounds to gain access to GRKs (Verspohl & Wienecke 
1998; Tang et al. 1998). Another technique used to investigate the involvement of 
GRKs in desensitization is to suppress the activity of the enzymes, either through the 
expression of dominant-negative mutant GRKs (Pitcher et al. 1998), or by reducing 
expression of the enzymes by treatment with antisense oligonucleotide sequences (Shih 
& Malbon 1994) or by stable expression of antisense mRNA (Shih etaL 1999). Exper-
iments using dominant-negative G RKs could be carried out most easily in a cell line 
endogenously expressing or transfected with the V1b receptor. Unfortunately the 
AtT -20 mouse corticotroph tumour cell line is not suitable since it does not respond to 
AVP (Lutz-Bucher et al. 1987). Antisense oligonucleotides reduce expression of pro-
teins by binding to mRNA, thereby preventing it from being translated (Phillips & 
Gyurko et al. 1997). Because cells can be treated with antisense sequences by adding 
the oligonucleotides directly to the culture medium (Shih & Malbon 1994; Aiyar et al. 
2000), this is probably the best technique for the investigation of the involvement of 
GRKs in desensitization of the pituitary AVP receptor in dispersed ovine anterior pitu-
itary cells. Although the ovine G RKs have not yet been cloned the G RK family is 
highly conserved, both amongst the different members of the family and across species 
(Pitcher et al. 1998), and as such it should be possible to design an oligonucleotide 
sequence which could inhibit expression of the ovine GRKs. 
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INVOLVEMENT OF RECEPTOR INTERNALIZATION AND 
PROTEIN PHOSPHATASES IN THE REGULATION OF 
THE ACTH RESPONSE TO AVP 
5.1 INTRODUCTION 
The results described in Chapter 3 show that the rapid desensitization of the ACTH 
response to AVP is readily reversible. Resensitization is itself rapid) with complete 
recovery of the response occurring within 40 min. The aim of the research described in 
this chapter was to investigate the molecular mechanisms underlying this process. In 
particular, the involvement of receptor internalization and protein phosphatase activity 
in the regulation of the ACTH response to AVP was investigated. 
Receptor endocytosis plays an important role in the regulation of many GPCRs 
(Ferguson 2001). However) evidence suggests the role of this process in both desensiti-
zation and resensitization varies from one receptor to the next. Based largely upon 
investigation of the P2-adrenergic receptor) a model has been proposed in which recep-
tor internalization does not mediate desensitization but instead is necessary for receptor 
resensitization (Ferguson etal.1996b). In this model internalization allows dephospho-
rylation of phosphorylated) desensitized receptors to take place. The receptors are sub-
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sequently recycled back to the plasma membrane in a fully functional state. Studies of a 
variety of GPCRs, including the NKl neurokinin receptor (Garland et al. 1996), the 
CBl cannabinoid receptor (Hsieh et at. 1999) and the o-opioid receptor (Hasbi et al. 
2000), have produced results consistent with this model. However more recently recep-
tor internalization has been shown to be necessary for the desensitization of a small 
number of receptors. These include the sst2B somatostatin receptor (Beaumont et al. 
1998), the m2 muscarinic receptor when expressed in CHO cells (Tsuga et al. 1998a), 
and the secretin receptor (Holtmann et al 1996; Mundell & Kelly 1998)(see Section 
1.2.2 for a more extensive discussion). 
Both the VIa and V2 AVP receptors are internalized following agonist exposure 
and this processplays an important role in their regulation (Lutz et at. 1991). However, 
the role of internalization in the regulation of these two receptors appears to differ. 
Whereas the VIa receptor is rapidly de phosphorylated and recycled back to the plasma 
membrane, the V2 receptor is retained in an intracellular compartment (Innamorati et 
al 1998a; Innamorati et al. 1998b). This is apparently due to a cluster of serine residues 
in the C terminal tail of the receptor which prevents dephosphorylation and recycling 
of the receptor back to the cell surface. Pfeiffer et al. (1998) found that treatment with 
hypertonic sucrose, which disrupts receptor-mediated endocytosis (Daukas & Zig-
mond 1985), significantly reduced the extent ofV2 receptor desensitization, suggesting 
that desensitization was dependent upon receptor sequestration. 
The pituitary AVP receptor is internalized during AVP treatment. Following 
exposure of rat anterior pituitary cells to eH]-AVP the amount of bound radiolabelled 
AVP that was acid-resistant (i.e. internalized) increased to a maximum over approxi-
mately 20 min (Mogensen et at. 1988). Internalization of bound biotinylated AVP and 
GFP-tagged Vlb receptors has been visualized following agonist exposure in rat ante-
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rior pituitary cells (Childs et al. 1991) and stably transfected CHO cells (Berrada et al. 
2000) respectively. The role of receptor internalization in the regulation of responsive-
ness is unknown. The first aim of the following experiments was to investigate the role 
of receptor endocytosis in both desensitization and resensitization of the ACTH 
response to AVP, by observing the effect on these two processes of pharmacologically 
blocking internalization. 
As described above, a key role of receptor internalization is to allow dephosphory-
lation by protein phosphatases before they are recycled back to the plasma membrane 
(Sibley et al 1986; Pippig et al 1995). Two different types of protein phosphatase, 
PP2A and PP2B have been implicated in the dephosphorylation ofGPCRs. Pitcher et 
al. (1992) were the first to demonstrate the involvement ofPP2A in the dephosphory-
lation of a GPCR, showing that the enzyme dephosphorylated both Pradrenergic and 
{X2-adrenergic receptors. Consistent with its involvement in resensitization, pharmaco-
logical inhibition of PP2A has been shown to attenuate the recovery of responsiveness 
of a number of GPCRs including the Pradrenergic receptor (Pippig et al. 1995) and 
the NKl neurokinin receptor (Grady etal. 1995; Garland etal. 1996). Similarly, phar-
macological inhibition of the Ca2+ Icalmodulin-dependent protein phosphatase PP2B 
(also known as calcineurin) or suppression of its expression can slow the rate of resensi-
tization of the Pradrenregic receptor (Shih & Malbon 1996; Shih et al. 1999). This 
phosphatase has been implicated in the resensitization of the 5-HT lC serotonin recep-
tor (Boddeke et al. 1991), the o-opioid receptor (Ueda et al. 1995) and muscarinic 
receptors in Xenopus oocytes (Sakuta etal1991). 
Both PP2A and PP2B have been shown to be involved in the regulation of 
responsiveness of AtT-20 mouse corticotroph tumour cells. Inhibition ofPP2A reduces 
CRH-stimulated cAMP accumulation (Koch & Lutz-Bucher 1994; Antaraki et al. 
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1997). In contrast, inhibition of PP2B increases basal ACTH secretion and CRH-
stimulated cAMP accumulation and ACTH secretion (Antoni et al. 1993). Although 
this suggests that these two enzymes are expressed in corticotrophs their roles in the 
regulation of the ACTH response are unclear. The second aim of the following experi-
ments was to investigate the involvement of PP2A and PP2B in the regulation of 
resensitization of the ACTH response to AVP. Selective inhibitors of these enzymes 
were used to reduce their activity, and the effect of this treatment on the time course of 
resensitization was assessed. 
5.2 RESULTS 
5.2.1 EXPERIMENTAL PROTOCOL 
Experiments were carried out using the multi-column perifusion system (see Section 
2.4.1). The protocol was similar to that used to investigate the resensitization of the 
ACTH response to AVP, which is described in detail in Section 3.2.4. Briefly, cells 
were stimulated with a single 5 min pulse with 100 nM AVP after 160 min of perifu-
sion, resulting in a characteristic peak of ACTH secretion. To induce desensitization 
this pulse was immediately preceded by a 15 min pre-treatment with 10 nM AVP. A 
recovery period of either 20 or 40 min duration was allowed between the end of the 
pre-treatment and the start of the pulse. The extent of desensitization present was 
assessed quantitatively by expressing the response to the 100 nM AVP pulse following 
pre-treatment as a percentage of the response of control cells (which were not pre-
treated) to similar 100 nM AVP pulses. 
The involvement of both receptor internalization and protein phosphatase activity 
in the regulation of the ACTH response to AVP was investigated by using pharmaco-
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logical agents to inhibit these two processes. Ce11s were treated with the appropriate 
pharmacological agent for 70 min prior to the 100 nM AVP pulse (i.e. from 90 min to 
160 min). The agent was present at a constant concentration throughout this period, 
i.e. before, during and after the pre-treatment. The effect of this treatment on the 
extent of AVP-induced desensitization was assessed quantitatively by expressing the 
response to the 100 nM AVP pulse following pre-treatment as a percentage of the 
response to AVP pulses of control cells which were treated with the pharmacological 
agent but which were not pre-treated with 10 nM AVP. 
5.2.2 EFFECT OF BLOCKADE OF RECEPTOR INTERNALIZATION ON THE REGULATION 
OF THE ACTH RESPONSE TO 1\vp 
5.2.2.1 CONCANAVALIN A 
Concanavalin A (ConA) is a lectin derived from the Jack Bean (Canavaiia ensiformis) 
and has an affinity for a-D-mannosyl and a-D-glucosyl residues (Reeke et al 1974; Lis 
& Sharon 1986). Treatment with this agent irreversibly cross-links glycosylated mem-
brane proteins such as GPCRs to one another (Lis & Sharon 1986), thereby preventing 
them from being internalized (Waldo et al. 1983; Pippig et al 1995). Treatment with 
ConA has been widely used to inhibit the internalization of a variety of GPCRs, e.g. 
see Lohse et ai. (1990a), Blaukat & Muller-Esterl (1997), Mundell & Kelly (1998) and 
Gardner et ai. (2001). 
In the control experiment, in which cells were not treated with ConA, pre-treat-
ment with 10 nM AVP for 15 min immediately prior to the 100 nM AVP pulse caused 
a reduction in response of 58.4 ± 4.4% (P<O.OOl, One way ANOVA with Bonferroni's 
test) compared with control (Fig.5.1a, b). When a recovery period was allowed 
between the pulse and the pre-treatment, resensitization occurred (Fig. 5.1c, d). After a 
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Fig. 5.1. Effect of treatment with 0.25 mg/ml ConA on the ACTH response to AVP. Repre-
sentative data from 8 independent perifusion columns are shown. Cells were treated with a 
5 min pulse of 100 nM AVP after 160 min of perifusion (indicated by arrows). To induce 
desensitization this AVP pulse was immediately preceded by a 15 min pre-treatment with 
10 nM AVP (indicated by black bars) (b, D. When recovery periods of 20 or 40 min were 
allowed between the pre-treatment and the pulse resensitization occurred (c, d, g, h). The effect 
of pharmacological blockade on regulation of the ACTH response to AVP was investigated by 
treating cells with 0.25 mg/ml for 70 min prior to the 100 nM AVP pulse (e to h). 
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20 min recovery period no significant desensitization remained (NS, Bonferroni's test); 
i.e. resensitization was complete. When cells were treated with 0.25 mg/ml ConA for 
70 min prior to the 100 nM AVP pulse AVP pre-treatment was still able to induce a 
desensitization but it was significandy reduced compared to that observed in the con-
trol experiment. When the AVP pre-treatment immediately preceded the 100 nM 
AVP pulse the response was reduced by 22.7 ± 3.7% (P<0.05, Bonferroni's test) com-
pared to the response of cells which were not pre-treated but were treated with ConA 
(Fig. 5.1e, f). This effect of treatment with ConA on the ability of pre-treatment with 
10 nM AVP for 15 min to induce desensitization was statistically significant (P<O.Ol, 
Bonferroni's test). Following recovery periods of20 and 40 min there was no significant 
difference between the extent of desensitization observed in control and ConA -treated 
cells. Results are summarized in Fig. 5.2. 
Treatment with ConA had no significant direct effect on ACTH secretion. 
Although the ACTH response to the 10 nM AVP pre-treatment was slightly less 
(approximately 15% at each of the time points) during treatment with 0.25 mg/ml 
ConA this was not statistically significant (Fig. 5.3). Similarly, in columns which 
received no AVP pre-treatment the ACTH response to the 100 nM AVP pulse was 
unaltered by prior exposure to 0.25 mg/ml ConA. Basal ACTH secretion was 
unaffected by treatment with ConA. 
5.2.2.2 HYPERTONIC SUCROSE 
Treatment with hypertonic sucrose inhibits receptor-mediated endocytosis without 
affecting fluid phase endocytosis (Daukas & Zigmond 1985). This selective inhibition 
of receptor-mediated endocytosis occurs because the treatment prevents the normal 
formation of clathrin-coated pits (Heuser & Anderson 1989). Treatment with hyper-
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Fig. 5.2. Effect of treatment with 0.25 mg/ml ConA on desensitization and resensitization of 
the ACTH response to AVP. The ACTH response after pre-treatment with 10 nM AVP for 
15 min is plotted against the duration of the recovery period. Combined results from columns 
in which ConA was present (e) and absent (i.e. controls; 0) are shown. Data are mean ± SEM 
(n=5-8). 
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Fig. 5.3. Effect of treatment with 0.25 mg/ml ConA on the ACTH response to the 15 min pre-
treatment with 10 nM AVP. The ACTH response to the AVP pre-treatment during ConA 
treatment (closed bars) is expressed as a percentage of the response to similar pre-treatments in 
control columns (open bars). Because the AVP pre-treatments started at different times 
depending upon the duration of the recovery period cells were treated with ConA for different 
durations prior to the beginning of the AVP pre-treatment. Data are mea n ±SEM (n=2-6). 
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tonic sucrose is commonly used to inhibit the internalization of GPCRs,'e.g. see Pippig 
etal (1995), Ng et al. (1995), Mundell & Kelly (1998) and Pfeiffer et al. (1998). 
Unlike ConA treatment, which did not affect ACTH secretion, treatment with 
KRI ATC made hypertonic with 004 M sucrose had significant effects on both basal and 
AVP-stimulated ACTH secretion. Following the onset of hypertonic sucrose treatment 
there was a small but significant increase in basal ACTH secretion (e.g. see Fig. 504e, to 
h). Furthermore, following treatment with hypertonic sucrose there was a 4.0-fold 
increase in the ACTH response to the 100 nM AVP pulse (n=4, P<O.Ol, t-test)(e.g. 
compare Fig. 504a and Fig. 504e). 
Despite these effects on ACTH secretion, treatment with hypertonic sucrose 
appeared to prevent AVP-induced- desensitization from occurring. When 004 M 
sucrose was present in the perifusion medium pre-treatment with 10 nM AVP was 
unable to induce any reduction in the response to a subsequent stimulation with 
100 nM AVP (NS, Bonferroni's test). There was a significant difference between the 
extent of desensitization induced by AVP pre-treatment in control and hypertonic 
sucrose-treated cells (P<O.OOl, Bonferroni's test). There was no significant difference 
between the ACTH response of control and hypertonic sucrose-treated cells following 
recovery periods of either 20 or 40 min (NS, Bonferroni's test). Results of experiments 
with hypertonic sucrose are summarized in Fig. 5.5. 
5.2.2.3 PHENYLARSINE OXIDE 
Treatment with the trivalent oxidizing agent phenylarsine oxide (PAO) inhibits recep-
tor internalization (Wiley & Cunningham 1982; Knutson et al. 1983; Griendling et al. 
1987; Garland etal. 1996; Sanders & LeVine 1996). PAO prevents endocytosis by irre-
versibly cross-linking membrane proteins containing sulfhydryl groups to one another 
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Fig. 5.4. Effect of treatment with hypertonic sucrose on the ACTH response to AVP. Represen-
tative data from 8 independent perifusion columns are shown. The experimental protocol used 
was identical to that described in Fig. 5.1, except that instead of ConA cells were treated with 
KRI ATC made hypertonic with 0.4 M sucrose for 70 min immediately prior to the 100 nM 
AVP pulse (e to h). 
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(Schelling & Linas 1994). In addition to preventing receptor internalization treatment 
with PAO has been reported to have effects on a variety of other cellular processes. 
These effects include the inhibition of tyrosine phosphatase activity (Massol et al. 
1998), the inhibition ofNADPH oxidase (Le Cabec & Maridonneau-Parini 1995) and 
the inhibition of caspases (Takahashi et al. 1997). Treatment with S flM PAO for 
70 min completely abolished the ACTH response to a subsequent stimulation with 
100 nM AVP. Therefore this was not a useful agent for assessing the role of in terna liz a-
tion in either desensitization or resensitization. 
5.Z.3 EFFECT OF INHIBITION OF PROTEIN PHOSPHATASES ON RESENSITIZATION OF 
THE ACTH RESPONSE TO AVP . 
5.Z.3.1 FK506 
FKS06 is a macrocyclic lactone derived from Streptomyces sp. which specifically inhibits 
PP2B (Schreiber 1991). This inhibition is indirect: FK506 first binds to an FK506-
binding protein and the resulting complex inhibits PP2B (Liu et al. 1991; O'Keefe et al. 
1992). The FK506 used in the following experiments was provided as a kind gift by Dr. 
M. Tomoi of the Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan. 
Cells were treated with FK506 at two concentrations: 50 nM and 1 f.1M. At these 
concentrations FK506 did not change the magnitude of desensitization induced by pre-
treatment with 10 nM AVP for 15 min (54.6 ± 6.4% in the presence of 1 flM FK506 
compared with 53.7 ± 3.5% in controls not treated with the inhibitor [P<O.Ol, Bonfer-
roni's test]). However, treatment with FK506 decreased the rate of resensitization. In 
the absence of FK506 recovery from desensitization was complete after 20 min 
(9.2 ± 5.1% less than control; NS, Bonferroni's test). In contrast, when cells were 
treated with 1 f.1M FK506 a significant desensitization still remained at 20 min 
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(38.1 ± 3.3% less than control; P<0.001, Bonferroni's test). Resensitization was not 
complete until 40 min. Representative data from individual columns in which cells 
were treated with 111M FK506 are shown in Fig. 5.6 and summarized results are 
shown in Fig. 5.7. 
In addition to this effect on the rate of resensitization, treatment with FK506 also 
caused a small but reproducible increase in AVP-stimulated ACTH secretion. Treat-
ment with both 50 nM and 1 11M FK506 increased the ACTH response to the 15 min 
10 nM AVP pre-treatment (see Fig. 5.8). Treatment with FK506 had no significant 
effect on either the ACTH response to the 100 nM AVP pulse or basal ACTH secre-
tion. 
5.2.].2 OKADAIC ACID 
Okadaic acid (OA) is a polyether fatty acid which inhibits protein phosphatase activity 
(Cohen 1990). It specifically inhibits the activity of both protein phosphatase 1 (PP1) 
and PP2A potently (Herzig & Neumann 2000). PP2A is completely inhibited by 
1 nM OA in a cell-free enzyme system, whereas PP1 is unaffected by this concentra-
tion, its IC50 being 10-15 nM (Cohen et al. 1989). Similar experiments have shown 
that PP2B is relatively unaffected by OA, with an IC50 of 3600 nM (Bialojan et al. 
1988). Treatment with 10 nM OA for 70 min prior to the 100 nM AVP pulse had no 
effect on the pattern of desensitization and resensitization observed following pre-
treatment with 10 nM AVP for 15 min. Results are summarized in Fig. 5.9. No evi-
dence could be found for an effect of treatment with 10 nM OA on either basal or 
AVP-stimulated ACTH secretion. 
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Fig. 5.6. Effect of treatment with 1 JlM FK506 on the ACTH response to AVP. Representative 
data from 8 independent perifusion columns are shown. The experimental protocol used was 
identical to that described in Fig. 5.1, except that instead of ConA cells were treated with 1JllY. 
FK506 for 70 min immediately prior to the 100 nM AVP pulse (e to h). 
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Fig. 5.9. Effect of treatment with 10 nM OA on desensitization and resensitization of the 
ACTH response to AVP. The ACTH response after pre-treatment with 10 nM AVP for 
15 min is plotted against the duration of the recovery period. Combined results from columns 
in which OA was present (CD) and absent (i.e. controls; 0) are shown. Data are mean ± SEM 
(n=2-1O). 
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5.2.3.3 CALYCULIN A 
Like OA, Calyculin A (CalyA) is a phosphatase inhibitor which inhibits both PP1 and 
PP2A (Herzig & Neumann 2000). It is equally potent against PP1 and PP2A (Ishihara 
et al. 1989). Mter the commencement of treatment with 50 nM CalyA there was a 
steady increase in the rate of basal ACTH release. ACTH secretion increased from 
35.5 ± 4.4 pg/min at 90 min to 129.1 ± 7.2 pg/min at 160 min (P<O.Ol, n=4, t-test). 
This effect on basal ACTH secretion confounded interpretation of this experiment and 
it was not possible to assess the effect of treatment with CalyA on either resensitization 
of the ACTH response to AVP or on AVP-stimulated ACTH secretion. 
5.3 DISCUSSION 
Taken together, the results of experiments in which receptor internalization was 
blocked pharmacologically indicate that internalization plays an important role in the 
regulation of the ACTH response to AVP. Treatment with 0.25 mg/ml ConA reduced 
the extent of desensitization induced by pre-treatment with 10 nM AVP for 15 min by 
approximately two-thirds. This effect on desensitization occurred without any signifi-
cant effect on either basal or AVP-stimulated ACTH secretion. The small and statisti-
cally insignificant decrease in AVP-stimulated ACTH secretion during the pre-
treatment might have been due to ConA hindering the interaction of AVP with its 
receptor. In any event such a small reduction in stimulation could not account for the 
large reduction in the magnitude of desensitization that was caused by ConA treat-
ment. 
Additionally, treatment with hypertonic sucrose (which blocks receptor-mediated 
endocytosis (Daukas & Zigmond 1985; Heuser & Anderson 1989) reduced the ability 
of AVP pre-treatment to induce a reduction in response to a subsequent AVP stimula-
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tion. Hypertonic sucrose completely abolished the AVP-induced reduction in response. 
However, this treatment caused significant non-specific effects: basal ACTH secretion 
was increased and the response to the 100 nM AVP pulse was greatly increased. These 
results suggest that the effects of hypertonic sucrose on the cells were not confined to 
the inhibition of receptor-mediated endocytosis. Because of these apparently non-
specific effects of hypertonic sucrose on ACTH secretion it is difficult to unambig-
uously interpret these results with regard to the effects of this treatment on the pro-
cesses of desensitization and resensitization. 
Treatment with 5 11M PAO for 70 min prevented 100 nM AVP from stimulating 
any ACTH secretion. Thus this agent could not be used to assess the role of internal-
ization in either desensitization or resensitization. Garland et al (1996) have reported 
that they were unable to maintain the viability of CH 0 cells treated with 80 11M PAO 
for 60 min. A similar problem may have been encountered in these experiments or, 
alternatively, a non-specific effect ofPAO may have prevented ACTH secretion. 
In summary, the data obtained with ConA showed that desensitization of the 
ACTH response to AVP is dependent to a large extent upon receptor internalization. 
Given the effects of hypertonic sucrose on both basal and AVP-stimulated ACTH 
secretion there is doubt whether the effect of this treatment on the ability of AVP to 
induce desensitization was in fact the result of blockade of receptor internalization. 
However, while hypertonic sucrose treatment is unlikely to be entirely specific (Beau-
mont et al. 1998), it is important to note that it affected AVP-induced desensitization 
in the same way as ConA, i.e. it inhibited it. 
The most convincing results in this series of experiments were those obtained by 
using ConA to inhibit internalization. It is interesting that treatment with 0.25 rog/rol 
ConA only partially inhibited the ability of AVP pre-treatment to induce desensitiza-
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tion. Treatment with the agent at this concentration has been shown, in some instances 
to completely inhibit receptor internalization. Lohse et al. (1990a) showed that during 
treatment with isoproterenol for 10 min, 30% of ~Tadrenergic receptors became inac-
cessible to the hydrophilic ligand CGP 12177, as measured by its ability to displace 
1251 -cyanopindolol binding. This sequestration of the receptor could be prevented by 
20 min pre-treatment with 0.25 mg/ml ConA. Pippig et al. (1995) obtained identical 
results using the same experimental system. Similarly, Ng et al. (1995) found that treat-
ment with 0.25 mg/ml ConA for 45 min completely inhibited internalization of the D1 
dopamine receptor, as measured by subcellular fractionation and radio ligand binding. 
In contrast, Trincavelli et al. (2000) found that treatment with the same concentration 
of ConA for 15 min inhibited internalization of the A3 adenosine receptor (as mea-
sured by radioligand binding) by only 51%. If receptor internalization was completely 
inhibited in the perifused anterior pituitary cell system used in these experiments then 
the remaining desensitization must have been the result of another desensitization pro-
cess or processes (see below). Alternatively, ConA treatment may have only partially 
inhibited receptor internalization and as a result only partially inhibited the develop-
ment of desensitization. 
The results of experiments in which selective inhibitors were used to inhibit phos-
phatase activity show that dephosphorylation by PP2B plays an important role in the 
resensitization of the ACTH response to AVP. Treatment with the highly specific 
PP2B inhibitor FK506 at a concentration of 1 11M significantly attenuated the rate of 
resensitization. No evidence could be found for the involvement ofPP2A in resensiti-
zation of the ACTH response to AVP. Treatment with 10 nM OA did not affect the 
rate of resensitization. Because of the non-specific effects of 50 nM CalyA treatment 
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on ACTH secretion this agent could not be used to assess the role of dephosphoryla-
tion in resensitization. 
The involvement ofPP2B in resensitization the ACTH response to AVP strongly 
suggests that phosphorylation of one or more components of the signalling pathway 
plays a role in the desensitization of the ACTH response to AVP. As described in Sec-
tion 1.2.1 receptor phosphorylation is a very common mechanism of rapid desensitiza-
tion amongst the GPCRs. The role of PP2B in resensitization has been most 
extensively investigated for the ~Tadrenergic receptor. Inhibition of PP2B activity, 
either by treatment with 122 nM FK506 (Shih & Malbon 1996) or expression of a 
PP2B antisense oligonucleotide sequence (Shih et al. 1999), prolongs recovery from 
desensitization of the cAMP responses to isoproterenol stimulation of this receptor. In 
the same system desensitization was found to be dependent upon GRK2 activity, indi-
cating that the receptor was phosphorylated during desensitization (Shih & Malbon 
1994). Although it has not been shown directly that PP2B dephosphorylates the ~T 
adrenergic receptor, co-immunoprecipitation experiments have shown that PP2B asso-
ciates with the receptor soon after agonist stimulation (Shih et al. 1999; Fraser et al. 
2000) providing strong circumstantial evidence that the role ofPP2B in resensitization 
is to dephosphorylate the receptor. It is possible that PP2B plays a similar role in the 
regulation of the ACTH response to AVP, mediating the dephosphorylation of V1b 
receptors phosphorylated during desensitization. However, because a wide variety of 
membrane and cytosolic proteins are phosphorylated during AVP stimulation (Liu 
1994; Liu et at. 1994) it is not possible, based on the data presented here, to exclude the 
possibility that dephosphorylation of proteins other than the A VP receptor is involved 
in resensitization. However, much of the phosphorylation which occurs during AVP 
stimulation is mediated by PKC and is involved in ACTH secretion (Abou-Samra et al. 
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1986; Carvallo & Aguilera 1989; Liu et al. 1990; Liu 1994; Liu et al. 1994). Results 
described in Chapter 4 show that PKC is not involved in the desensitization of the 
ACTH response to AVP: activation of PKC did not cause desensitization and inhibi-
tion of PKC activity did not prevent AVP pre-treatment from inducing desensitization. 
While reversal of PKC-mediated phosphorylation by PP2B might be involved in the 
regulation of ACTH secretion (see below) this is unlikely to playa role in resensitiza-
tion, given that PKC does not mediate desensitization of the ACTH response to AVP. 
Furthermore this observation suggests that desensitizing phosphorylation is not medi-
ated by PKC or any protein kinase downstream from it in the signalling pathway. This 
is consistent with the involvement of GRK-mediated phosphorylation in desensitiza-
tion of the V1b .receptor. 
If the role of PP2B in resensitization of the ACTH response to AVP is to dephos-
phorylate desensitized Vlb receptors, then the question of what role receptor 
phosphorylation plays in desensitization is raised. Typically, phosphorylation of 
GPCRs causes desensitization by inhibiting the interaction of the receptor with its 
associated G protein, uncoupling it from its signalling pathway (Lohse 1993). Phos-
phorylation of receptors by the effector kinases (i.e. PKA or PKC) is, in itself, sufficient 
to cause desensitization whereas G RK -mediated phosphorylation is not (Benovic et al. 
1988). Binding of ~-arrestins to the phosphorylated receptor is necessary to terminate 
signalling (Lohse et al 1990b). Therefore receptor phosphorylation is usually, directly 
or indirectly, sufficient to induce desensitization, i.e. internalization of the receptor is 
not required for its desensitization. However, it has been shown here that desensitiza-
tion of the ACTH response to AVP can, to a large extent, be inhibited by pharmaco-
logical blockade of receptor internalization, indicating that receptor sequestration is 
important in the desensitization process. One possibility is that there are dual mecha-
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nisms of desensitization, with receptor phosphorylation mediating the proportion of 
desensitization which could not be inhibited by treatment with ConA. A model of 
desensitization similar to this has been proposed for the secretin receptor. This receptor 
is a member of the Class II GPCR family, members of which share little structural 
homology with the Class I (or p-adrenergic) family of receptors of which the V1b 
receptor is a member (Gether 2000). During agonist exposure the secretin receptor 
undergoes GRK-mediated phosphorylation at serine and threonine residues in its C 
terminal tail (Ozcelebi et ai. 1995; Shetzline et ai. 1998). The receptor is also internal-
ized following agonist exposure (Holtmann et ai. 1996). Truncation of the C terminal 
tail of the receptor abolished phosphorylation of the receptor and partially inhibited 
desensitization. Internalization of the receptor was unaffected by this truncation and it 
was presumed that this process accounted for the remainder of desensitization (Holt-
mann et al 1996). This conclusion was supported by studies in which pharmacological 
blockade of internalization with either hypertonic sucrose or ConA was shown to 
reduce the extent of desensitization induced by secretin treatment (Mundell & Kelly 
1998). 
Another possible role for receptor phosphorylation in the regulation of the V1b 
receptor is as a signal which acts to promote receptor sequestration. Phosphorylation, 
and in particular GRK-mediated phosphorylation, plays an important role in the inter-
nalization of a variety of GPCRs including the PTadrenergic receptor (Ferguson et ai. 
1995; Menard et al1996), the m2 muscarinic receptor (Tsuga et ai. 1998b), the endo-
thelin A receptor (Bremnes et al 2000) and the follicle stimulating hormone receptor 
(Lazari et ai. 1999). In the case of the P2-adrenergic receptor GRK-mediated 
phosphorylation is not absolutely required for internalization but instead increases the 
affinity of the receptor for p-arrestins which, in addition to uncoupling the receptor 
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from its signalling pathway, bind the ~Tadaptin subunit of the AP-2 adaptor complex 
which targets the receptor for internalization via clathrin-coated pits (Ferguson et al. 
1996a; Laporte et al. 1999; Laporte et al. 2000; Ferguson 2001). It is possible that 
phosphorylation of the V1b receptor occurs at a site which does not prevent the recep-
tor from interacting with Gq/ll but targets the receptor for internalization. It should be 
noted that receptor internalization can occur in the absence of receptor phosphoryla-
tion (Hausdorff et al. 1989; Ferguson et al. 1995). Indeed phosphorylation-independent 
internalization appears to be the main mechanism of desensitization of the sst2B soma-
tostatin receptor. Desensitization of signalling via this receptor is unaffected by inhibi-
tion of the activity of GRK2, GRK3, PKA, PKC and protein kinase G but can be 
abolished by treatment with PAO, -hypertonic sucrose and ConA (Beaumont et al. 
1998). 
These two hypotheses for a role of receptor phosphorylation in the desensitization 
of the pituitary AVP receptor are not necessarily mutually exclusive. The actual mecha-
nism could consist of a combination of the two. Receptor phosphorylation and subse-
quent binding of ~-arrestins could impair, but not completely prevent, coupling of the 
V1b receptor to Gq/ll , with subsequent phosphorylation-dependent internalization of 
the receptor resulting in full desensitization. 
The increase in AVP-stimulated ACTH secretion during treatment with FK506 is 
an interesting phenomenon. As described above, protein phosphorylation, and particu-
larly PKC-mediated phosphorylation, plays an important role in AVP-stimulated 
ACTH secretion. Clearly, for this protein phosphorylation to act as a reversible signal-
ling system these target proteins must be dephosphorylated by protein phosphatases, 
resulting in termination of the response. The increase in ACTH secretion which we 
have observed during FK506 treatment is likely to have been the result of persistent 
II3 
ROLE OF INTERNALIZATION AND PROTEIN PHOSPHATASES IN DESENSITIZATION 
phosphorylation of these target proteins as a consequence of PP2B inhibition. PP2B 
has been reported to be involved in the regulation of a variety of cellular processes 
(Armstrong 1989), but the data presented here do not give any clue as to the sites of 
action ofPP2B in ovine corticotrophs. One possible target ofPP2B-mediated dephos-
phorylation is the myristoylated alanine-rich cytosolic kinase substrate (MARCKS) 
protein. This widely expressed protein is phosphorylated by PKC during AVP stimula-
tion of ovine corticotrophs and this is associated with ACTH secretion (Liu et al. 
1994). In vitro, PP2B has been shown to dephosphorylate MARCKS (Seki et al. 1995). 
Inhibition of PP2B-mediated dephosphorylation of MARCKS could result in 
increased ACTH secretion. Another possible substrate for dephosphorylation are L-
VSCC. In Section 4.3 the possibility that PKC-mediated phosphorylation may posi-
tively modulate L-VSCC in ovine corticotrophs was discussed. PP2B has been shown 
to play an important role in the regulation of L-VSCC, dephosphorylating the chan-
nels and rendering them inactive (Armstrong et al. 1989; Lai et at. 1993; Schuhmann et 
al. 1997). Removal of a feedback mechanism of this type by inhibition of PP2B could 
prolong L-VSCC activation in corticotrophs, thereby increasing AVP-stimulated 
ACTH secretion. Interestingly, PKC and PP2B have been shown to regulate the activ-
ity ofVSCC in this manner in rat lactotrophs (Fomina & Levitan 1997). 
Antoni et al. (1993) have reported that treatment with 1 flM FK506 increases 
basal ACTH secretion of AtT-20 ce11s. No evidence for such an effect in ovine anterior 
pituitary ce11s could be found in these experiments. The magnitude of such an effect 
may have been too small to detect. 
In summary, these results show that desensitization of the ACTH response to 
A VP depends to a large extent, if not entirely, upon receptor internalization. As such 
the pituitary A VP receptor joins the small group of GPCRs for which internalization is 
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important in desensitization. Also, the activity of PP2B plays an important role in 
resensitization, most likely by dephosphorylating pituitary AVP receptors. 
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DISCUSSION 
6.1 SUMMARY 
Desensitization of the ACTH response to AVP was investigated in a perifused dis-
persed ovine anterior pituitary cell system. Characterization of the desensitization pro-
cess showed that it was rapid, readily reversible and occurred at relatively low AVP 
concentrations (see Chapter 3). Significant desensitization was found to occur at con-
centrations and durations of AVP treatment which were within the range of endoge-
nous AVP pulses, suggesting that desensitization might play an important 
physiological role in the regulation of ACTH secretion. The rapidity of desensitization 
and resensitization suggested that these processes might be more important in regulat-
ing the acute ACTH response to AVP than in the alterations of corticotroph respon-
siveness which have been observed during chronic stress. 
The characteristics of the desensitization process also suggested that it might be 
mediated by phosphorylation of the pituitary AVP receptor, a common mechanism of 
desensitization amongst the GPCR family (Lohse 1993). No evidence could be found 
for the involvement of either PKC or CKla in desensitization of the ACTH response 
to AVP (see Chapter 4), but it remains possible that the Vlb receptor is phosphory-
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lated by another intracellular protein kinase, e.g. a member of the GRK family. The lack 
of involvement of PKC in desensitization suggests that there are AVP receptor sub-
type-specific differences in the mechanism of desensitization since the hepatic/vascular 
Vla AVP receptor has been shown to be desensitized by PKC (Caramelo et al 1991; 
Gallo-Payet et al 1991; Ancellin et al. 1997; Ancellin & Morel 1998). 
Internalization of GPCRs is commonly associated with their resensitization, 
allowing dephosphorylation of desensitized receptors before they are recycled back to 
the plasma membrane in a fully functional state (Ferguson 2001). However, it was 
found that pharmacological blockade of receptor internalization reduced the extent of 
desensitization induced by AVP treatment, indicating that receptor sequestration 
played a critical role in the desensitization process. Inhibition ofPP2B had no effect on 
desensitization but slowed the rate of recovery from desensitization, indicating that this 
enzyme was important in resensitization. The involvement of a protein phosphatase in 
resensitization is consistent with receptor phosphorylation playing an important role in 
desensitization (see Chapter 5). 
6.2 GENERAL COMMENTS ON METHODS USED IN THIS RESEARCH 
In this study the molecular mechanisms involved in the desensitization of the ACTH 
response to AVP have largely been investigated by examining the effects of various 
pharmacological agents on this desensitization process. Because the effects of these 
agents on cellular function have been assessed indirectly, without directly measuring 
their effects on the intended target, the possibility that observed effects are due to non-
specific actions is always present. This problem is particularly acute where the activity 
of a complex cellular function (such as endocytosis) rather than a specific target (such as 
an enzyme) is being modulated. Where possible this potential problem has been mini-
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mized through the use of multiple agents to investigate the involvement of a particular 
cellular process or enzyme in desensitization. Although each of the pharmacological 
agents used may have its own non-specific effects, these are likely to be different for 
each agent and can be identified and taken into account during analysis of the data. A 
good example of this approach is provided by the investigation of the involvement of 
receptor internalization in regulation of the ACTH response to AVP (see Chapter 5). 
Three agents (ConA, PAD and hypertonic sucrose), each of which is purported to 
inhibit internalization through a mechanistically distinct mechanism, were used to 
inhibit internalization. While none of these agents could be considered to be entirely 
specific (Beaumont et at. 1998), the combined results provided strong evidence that 
desensitization Was largely dependent upon internalization of the Vi b receptor. 
The use of this approach to investigate the mechanisms of desensitization was dic-
tated in part by the use of dispersed ovine anterior pituitary cells as the experimental 
system. Carrying out experiments in primary cultures made the use of a number of 
experimental techniques, particularly those involving molecular biology (e.g. expression 
of dominant negative mutant GRKs, truncation of the Vlb receptor tail), either 
impractical or impossible. While in one sense this could be seen as a disadvantage, use 
of this system did provide a distinct advantage. Recent evidence has shown that the 
level of expression of GPCRs can affect their regulation. For example, at low density 
the thromboxane A2 receptor becomes desensitized during agonist-exposure but at 
high receptor densities desensitization is not observed (Spurney 1998). Furthermore, 
regulation of GPCRs can vary depending upon the nature of the cellular environment 
in which they are expressed (Ferguson 2001). For example, the CXCRl interleukin-8 
receptor does not undergo agonist-promoted internalization when expressed in 
HEK293 cells but does when expressed in the neutrophil-like RBL-2H3 cell line, 
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which expresses substantially higher levels of GRK2 and ~-arrestin (Barlic et ai. 1999). 
Similarly, the extent of agonist-promoted internalization of the ~2-adrenergic receptor 
varies depending on the cell line in which the receptor is expressed, and the extent of 
receptor internalization was found to correlate well with the level of expression of 
GRKs and ~-arrestins (Menard et ai. 1997). These data suggest that the regulation of 
GPCRs is dependent not only on the presence or absence of specific proteins but also 
on the level of expression of these proteins. Because the cellular milieu in immortalized 
cell culture systems may be different to that found in physiological systems it is possible 
that there are important differences in the regulation of a given receptor in these two 
environments. (Ferguson 2001). This is especially likely to be the case in heterologous 
expression systems such as those deseribed above. In contrast, in the anterior pituitary 
cell system used in this research the expression of all components of the signalling path-
way were under physiological regulation. As such the mechanisms which were found to 
be involved in desensitization of the ACTH response to AVP are likely to be of physio-
logical significance and not artefacts of the system being investigated. 
This investigation of the mechanisms of desensitization of the ACTH response to 
AVP has focused on the regulation of the receptor, as in many instances regulation of 
GPCRs appears to account for most, if not all, of the observed desensitization (Krup-
nick & Benovic 1998). However, because ACTH secretion has been used as the indica-
tor of responsiveness to AVP it is possible that post-receptor mechanisms are involved 
in desensitization. For example, down-regulation of IP3 receptors plays an important 
role in desensitization of signalling through the PLC-coupled GnRH receptor (McAr-
dle et al 1999). The involvement of similar mechanisms in desensitization of the 
ACTH response to A VP cannot be excluded. 
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6.3 PHYSIOLOGICAL ROLE OF DESENSITIZATION OF THE ACTH RESPONSE TO 
AVP 
Secretion of AVP into the hypophyseal portal circulation is highly pulsatile, with secre-
tory episodes rarely lasting more than 30 min during acute stress in the sheep (Caraty et 
al. 1988; Engler et al 1989; Caraty et al. 1990). As described above and in greater depth 
in Chapter 3, desensitization was found to occur at concentrations and durations of 
AVP treatment which were within the ranges observed in endogenous AVP pulses. 
This suggests that this rapid desensitization might play an important physiological role 
in the regulation of ACTH secretion. Because desensitization was shown to be both 
rapid and readily reversible it is unlikely that it is responsible for the down-regulation of 
pituitary AVP receptors which has been observed in vivo during treatments such as 
prolonged AVP infusion (Antoni et al. 1985), adrenalectomy (Antoni et al. 1985; Lutz-
Bucher et al. 1986), and chronic osmotic stress such as hypertonic saline injection and 
2% saline in the drinking water (Aguilera et al. 1994). 
Down-regulation of GPCRs typically occurs following long-term agonist expo-
sure (i.e. hours or days) and can be achieved by either a reduction in the rate of receptor 
synthesis, increased degradation of existing receptors or a combination of these two 
processes (Lohse 1993). Internalization is known to playa key role in the resensitiza-
tion ofGPCRs. For example, following phosphorylation and desensitization ~Tadren-
ergic receptors are transferred from the cell surface to an intracellular compartment 
(most likely endosomes [von Zastrow & Kobilka 1992]), where they are dephosphory-
lated by protein phosphatases and then returned to the cell surface in a fully functional 
state (Yu et al 1993; Pippig et al. 1995; Ferguson 2001). However, internalization also 
plays an important role in the down-regulation of GPCRs. During long-term treat-
ment with isoproterenol (a treatment which induces down-regulation) GFP-tagged ~T 
adrenergic receptors expressed in HEK293 cells accumulate in lysosomes (Kallal et al. 
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1998). Gagnon et al. (1998) found that this internalization of the PTadrenergic recep-
tor played an important role in down-regulation. Expression of dominant-negative 
mutants of dynamin and p-arrestin inhibited both internalization and down-regulation 
of the receptor. It was concluded that during long-term stimulation some of the intern-
alized receptors were sorted from endosomes to lysosomes for degradation. 
In this study it has been shown that receptor internalization played a critical role in 
the desensitization of the ACTH response to AVP (see Chapter 5). Given that follow-
ing treatment with 10 nM AVP for 15 min complete resensitization occurred within 20 
to 40 min, it is likely that receptors were recycled back to the plasma membrane rather 
than targeted for lysosomal degradation. Because endogenous AVP pulses observed 
during acute stress are of similarly short duration and low concentration it is unlikely 
that they are able to cause down-regulation of the pituitary AVP receptor. Indeed, one 
function of the pulsatile secretion of AVP into the hypophyseal portal circulation may 
be to avoid prolonged stimulation of the receptor, thereby preventing its down-regula-
tion. However, it is possible that increases in the duration, concentration or frequency 
of AVP pulses during chronic stress could result in targeting of pituitary AVP receptors 
for lysosomal degradation rather than recycling back to the cell surface. Interestingly, 
Rabadan-Diehl et al. (1995) found little correlation between V1b receptor mRNA con-
tent and AVP binding in anterior pituitary cells isolated from rats exposed to various 
chronic stress paradigms. Although this lack of correlation could be explained by phe-
nomena such as increased mRNA utilization, especially in situations where the receptor 
was up-regulated (Aguilera & Rabadan-Dieh12000), it also suggests that degradation 
of existing receptors may play an important role in the down-regulation of pituitary 
A VP receptors. 
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It is possible that factors such as CRH and glucocorticoids are able to modulate 
the desensitization of the ACTH response to AVP. As described in Chapter 3, it has 
been demonstrated in our laboratory that desensitization of the ACTH response to 
AVP in perifused ovine anterior pituitary cells is unaffected by the presence of a low 
(0.01 nM) 'background' concentration of CRH in the perifusion medium (Chacko 
2000; Chacko et aL 2000). However, given that receptor internalization was found to be 
important in desensitization of the ACTH response to AVP it is interesting to note 
that treatment with CRH can increase the rate of internalization of the pituitary AVP 
receptor. Working with rat anterior pituitary cells, Mogensen et al. (1988) have shown 
that treatment with 21 nM CRH causes a marked increase in the rate of receptor-
mediated endocytosis of eHJAVP. This raises the possibility that CRH might be able 
to modulate the desensitization process in some way. CRH concentrations greater that 
the 0.01 nM treatment used by Chacko (2000) might be able to enhance desensitiza-
tion by promoting receptor internalization. Alternatively, a consequence of a CRH-
induced increase in the rate of AVP receptor internalization might be enhanced recy-
cling of the receptor, resulting in more rapid resensitization. 
6.4 SUGGESTIONS FOR FURTHER RESEARCH 
This study has shown that in perifused ovine anterior pituitary cells the ACTH 
response to AVP undergoes rapid desensitization, and has elucidated some of the 
mechanisms which underlie this desensitization process. However, a great many ques-
tions remain to be answered with regard to both the characterization of this process and 
the mechanisms which are involved. 
While Chacko (2000) has shown that treatment with CRH at physiological con-
centrations has no effect on desensitization of the ACTH response to AVp, neither 
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enhancing nor 'protecting' against desensitization, the effect of glucocorticoids on this 
process is unknown. Furthermore, it is possible that there are complex interactions 
between AVP, CRH and glucocorticoids (and possibly other factors) which affect the 
desensitization process in unanticipated ways. Further investigation of the effects of 
both CRH and glucocorticoids on desensitization could provide important insights 
into the physiological regulation of ACTH secretion. 
Although PKC and CK1o: were not involved in desensitization it remains likely 
that receptor phosphorylation plays an important role in the regulation of the ACTH 
response to AVP. In particular, the involvement of members of the G RK family in this 
process is yet to be elucidated. An investigation of the involvement of GRKs in desen-
sitization is currently in progress in our laboratory using treatment with oligonucleotide 
sequences to inhibit expression of GRKs. 
Attempts to show directly that the pituitary A VP receptor is phosphorylated dur-
mg agonist exposure were unsuccessful. Incorporation of phosphate into the V1b 
receptor could be shown by incubating cells with 32p and subsequently immunoprecip-
itating the receptor as has been described for Via receptor (Ancellin et ai. 1999) and 
the V2 receptor (Innamorati et ai. 1997). Use of this technique would require either 
anti-V1b receptor antibodies or an epitope-tagged V1b receptor. 
While receptor internalization has been shown to be important in desensitization 
of the ACTH response to A VP it is not clear what signals cause the receptor to become 
internalized. Both phosphorylation-dependent and independent internalization of 
GPCRs has been observed (Ferguson 2001). If a protein kinase were shown to be 
involved in desensitization it would be interesting to assess the effect of inhibition of 
this enzyme on internalization of the A VP receptor, which could be measured by radio-
ligand binding. 
123 
DISCUSSION 
Internalization of many GPCRs (e.g. ~Tadrenergic receptor [Pippig et al. 1995J, 
NKi neurokinin receptor [Garland et al 1996J) plays an important role in resensitiza-
tion, allowing the dephosphorylation of receptors at an intracellular location (Ferguson 
etal. 1996b). On the other hand, Bogatkewitsch etal. (1996) have shown that inhibi-
tion of internalization of the m4 muscarinic receptor delays its resensitization. The role 
of receptor internalization in resensitization of the ACTH response to AVP remains 
unclear. One approach to this problem would be to inhibit recycling of the pituitary 
AVP receptor. Both monensin (an ionophore) and bafilomycin Ai (an H+ / ATPase 
inhibitor) inhibit receptor recycling by raising endosomal pH (Pippig et al 1995; Gar-
land et al. 1996; Beaumont et al1998). If internalization were necessary for resensitiza-
tion then treatment with either of these agents would be expected to slow the rate of 
resensitization. 
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APPENDIX A 
MATERIALS 
[Arg8]-vasopressin, acetate salt 
0.22 11m polyethersulfone filter 
0.45 11m mixed cellulose ester filter 
1,2-dioctanoyl-sn-glycerol (DiC8) 
1251 
Acetone 
Acetonitrile 
Acrylamide 
ACTH with carboxymethylcellulose 
ACTH zinc hydroxide 
Ammonium persulphate 
Amphotericin B 
Bio-Gel P-2 
Bovine y-globulins 
Bovine serum albumin (purified) 
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Sigma Chemical Co. 
Millipore Corporation, Bedford MA 
Millipore Corporation, Bedford MA 
Sigma Chemical Co. 
Amersham International, 
Buckinghamshire, UK 
Amersham International, 
Buckinghamshire, UK 
BDH Laboratory Supplies 
BDH Laboratory Supplies 
Sigma Chemical Co. 
Nordic Biochemicals Ltd., Montreal, 
Canada 
Organon Laboratories, Surrey, UK 
Sigma Chemical Co. 
Sigma Chemical Co. 
Biorad Laboratories, Hercules CA 
Sigma Chemical Co. 
Behring, Marburg, Germany 
APPENDIX A 
Brilliant Blue G 
CaC12·2H20 
CalyculinA 
Cellulose 
Chloramine T 
CKl-7 
Concanavalin A 
D-glucose 
Dimethylsulphoxide (DMSO) 
Disuccinimidyl suberate (DSS) 
DMEpowder 
EGTA 
FK506 
Glacial acetic acid 
Glycine 
HCl 
HEPES 
Horse plasma 
KCl 
KH2P04 
L-ascorbic acid 
L-glutamate 
MEM non-essential amino acids 
MgS04·7H20 
N ,N' -Methylene bis-Acrylamide (B is) 
Na2HP04 
Na2S30S 
Sigma Chemical Co. 
Reidel-De Haen AG, Hannover, 
Germany 
Sigma Chemical Co. 
Whatman Ltd, Springfield Mill, Kent, 
UK 
BDH Laboratory Supplies 
Seikagaku Corporation, Tokyo, Japan 
Sigma Chemical Co. 
BDH Laboratory Supplies 
BDH Laboratory Supplies 
Pierce, Rockford IL 
Sigma Chemical Co. 
BDH Laboratory Supplies 
Dr. M. Tomoi, Fujisawa Pharmaceutical 
Co., Ltd., Osaka, Japan 
BDH Laboratory Supplies 
Sigma Chemical Co. 
BDH Laboratory Supplies 
Sigma Chemical Co. 
Endolab, Christchurch Hospital, 
Christchurch 
May and Baker Australia Ltd, West 
Footscray, Victoria, Australia 
BDH Laboratory Supplies 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
BDH Laboratory Supplies 
Sigma Chemical Co. 
BDH Laboratory Supplies 
BDH Laboratory Supplies 
Na3V04 
Na4P207·10H20 
NaCl 
NaF 
NaHC03 
NaN3 
NaOH 
New-born calf serum (NCS) 
Nybolt nylon gauze 
Okadaic acid 
OvineACTH 
Penicillin G 
Phenol red (sodium salt) 
Phenylarsine oxide 
Plastic petrie dishes 
Polyethylene glycol 6000 
Ro 31-8220 
Sephadex G-25 fine 
SigmaMarkers 
Silicic acid (100 mesh) 
Sodium dodecyl sulphate (SDS) 
Sterile culture tubes 
Streptomycin sulphate 
Sucrose 
TEMED 
Trichloroacetic acid (TCA) 
Tris 
Triton X -100 
APPENDIX A 
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Sigma Chemical Co. 
Sigma Chemical Co. 
BDH Laboratory Supplies 
BDH Laboratory Supplies 
BDH Laboratory Supplies 
BDH Laboratory Supplies 
BDH Laboratory Supplies 
Life Technologies, Rockville MD 
Seidengaze, Zurich, Switzerland 
Sigma Chemical Co. 
Dr C.H. Li, Hormone Research 
Laboratory, University of California, San 
Francisco CA 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Labserv, Auckland 
BDH and Scharlau Chemie, Barcelona, 
Spain 
Dr G. Lawton, Roche Research Centre, 
Welwyn Garden City, UK 
Sigma Chemical Co. 
Sigma Chemical Co. 
Mallinckrodt, St Louis MO 
Sigma Chemical Co. 
Falcon Labware, Franklin Lakes NJ 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
Sigma Chemical Co. 
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Trypan blue BDH Laboratory Supplies 
Type II collagenase (clostridiopeptidase A) Sigma Chemical Co. 
ns.p. Type VII gauze Kendall Healthcare Products, BostonMA 
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APPENDIXB 
SOLUTIONS 
B.I CELL PREPARATION AND CULTURE 
B.I.I DISPERSING BUFFER (DB) 
This solution was prepared by dissolving the reagents listed below in ddH20 to give 
the concentrations shown, The pH was adjusted to 7.3 using concentrated NaOH or 
HCl and the solution was sterilised by either negative pressure filtration (0,45 flm 
mixed cellulose ester [MCE] filter) or positive pressure filtration (0.22 flm polyether-
sulfone [PES] filter), The solution was stored at 4 "C, 
NaCI 
KCI 
N-[ 2-hydroxyehtyl]piperazine-
N'-2-ethanesulfonic acid (HEPES) 
D-Glucose 
Phenol red (sodium salt) 
Penicillin G 
I6I 
137mM 
5mM 
25mM 
lOmM 
42nM 
lOOU/ml 
Streptomycin sulphate 
Amphotericin B 
APPENDIX B 
100 fIg/ml 
0.25 fIg/ml 
B.I.2 DULBECCO'S MODIFIED EAGLES MEDIUM (DMEM) 
One bottle of commercially prepared, powdered medium was dissolved in ddH2G. The 
reagents listed below were added in quantities which gave the concentrations shown. 
The solution was made up to 1 L with ddH20, adjusted to pH 7.1 and sterilized by 
negative pressure filtration (0.45 flm MCE filter). If the solution to be used in cell cul-
ture was between 2 and 4 weeks old freshL-glutamate was added to give a final concen-
tration of 2 mM. The solution was stored at 4°C. Before use in cell culture 10% NCS 
was added. 
NaHC03 
HEPES 
MEM non-essential amino acids 
Phenol red (sodium salt) 
Penicillin G 
Streptomycin sulphate 
Amphotericin B 
B.2 MULTI-COLUMN PERIFUSION 
B.2.I KREBS RINGER (KR) 
44mM 
25mM 
1.0 ml 
53nM 
100 Dlml 
100 fIg/ml 
0.25 fIg/ml 
The reagents listed below were dissolved in ddH20 to give the concentrations shown. 
The pH was adjusted to 7.3 and the solution was filter-sterilised as for dispersing 
buffer. The solution was store at 4°C. On the day of use in a perifusion experiment 
APPENDIX B 
0.05% ATC and 0.005% L-ascorbate were added to give KRI ATC. If necessary the pH 
was adjusted to 7.3 after the addition of ATC and ascorbate. 
NaCI 125mM 
KCI 4.7mM 
CaC12,2H2O 2.5mM 
KH2P04 1.2 mM 
MgS04·7H2O 1.2 mM 
NaHC03 3,6mM 
HEPES 25mM 
Glucose 10mM 
Phenol red (sodium salt) 3.5 nM 
Penicillin G 100D/ml 
Streptomycin sulphate 100 fig/ml 
Amphotericin B 0.25 fIg/ml 
B.2.2 50 MM KCL KREBS RINGER 
This was produced by mixing normal KR (with a K+ concentration of 5.9 mM) with an 
appropriate volume of a 100 mM KCl solution. 100 mM KCl was produced by dissolv-
ing the reagents listed below in ddH20 to give the concentrations shown. The pH of 
the solution was adjusted to 7.3. It was filter-sterilised and stored at 4"C. 
NaCI 
KCl 
KH2P04 
CaC12.2H20 
85mM 
98.8 mM 
1.2mM 
2.5mM 
APPENDIX B 
KH2P04 1.2mM 
MgS04·7H2O l.2mM 
NaHC03 3.6mM 
HEPES 25mM 
Glucose 10mM 
Phenol red 3.5 nM 
Penicillin G 100U/ml 
Streptomycin sulphate 100 flg/ml 
Amphotericin B 0.25 flglml 
B.2·3 PREPARATION OF 'TEST' SOLUTIONS 
'Test' solutions for perifusion were prepared by either dissolving the hormone or phar-
macological agent direcdy in KRI ATC or diluting a stock solution with KRI ATC. 
Stock solutions of AVP were prepared at concentrations of 20 11M by dissolving the 
peptide ([Args]-vasopressin, acetate salt) in KR containing 0.3% bovine serum albumin 
and 0.005% L-ascorbic acid. These stock solutions were stored at -80aC and diluted in 
KRI ATC to give the desired concentration for perifusion experiments. DiCs, 
Ro 31-8220, Calyculin A, okadaic acid and FK506 were prepared as stock solutions in 
DMSo. ConA and sucrose were dissolved directly in KRiATC. 
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B.3 RADIOIMMUNOASSAY SOLUTIONS 
B.3.I STOCK 0.5 M PHOSPHATE BUFFER 
The following reagents were made up to 1 L in ddH20. This solution was used as a 
stock solution for other solutions and was stored frozen. 
Ethylenediamine tetraacetic acid 
(disodium salt; Na2EDTA) 
B.3.2 0.05 M PHOSPHATE/o.r% ATC BUFFER (p/ ATC) 
18 g 
52.3 g 
0.1 g 
2g 
0.5 M stock phosphate buffer was diluted 1:10 [v:v] to give a 0.05 M solution. 0.1% 
ATC was added and the pH was adjusted to 7.4. The solution was stored frozen. 
B.3.3 ACETONE/ACETIC ACID 
This was used in the repurification of ACTH tracer. It was prepared on the day of the 
repurification by mixing 2.5 ml of acetone and 100 III of glacial acetic acid with 10 ml 
B.3.4 POLYETHYLENE GLYCOL SOLUTION (PEG) 
An 18% polyethylene glycol solution was prepared using the reagents listed below and 
was stored at room temperature. 
PEG6000 
NaCl 
r65 
360 g 
11.7 g 
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0.5 M stock phosphate buffer 
Triton X -1 00 
210 g 
1500 g 
2ml 
B.4 SOLUTIONS FOR PREPARATION OF PLASMA MEMBRANES AND 
ELECTROPH ORESIS 
B.4.1 INHIBITOR BUFFER (IB) AND PROTEIN ASSAY BUFFER (PAB) 
To prepare IE the reagents listed below were dissolved in ddH20. The solution was 
made up to 250 ml, the pH adjusted to 7.4 and stored at -20oe. PAB was similar to IE 
but did not contain leupeptin or EGTA. PMSF was prepared in dried ethanol as a lOOx 
stock solution and added immediately before use. 
HEPES 
NaCl 
NaF 
Ethyleneglycolbis(aminoethylether)-
tetraacetic acid (EGTA) 
Leupeptin 
Phenylmethyisulfonylfluoride (PMSF) 
166 
25mM 
104mM 
lOmM 
2mM 
2mM 
20mM 
0.1mM 
1 fJ.g/ml 
ImM 
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B.4.2 POLYACRYLAMIDE GEL ELECTROPHORESIS 
B.4.2.1 RESERVOIR BUFFER 
Reservoir buffer for SDS-PAGE was prepared as a 5x solution and diluted immedi-
altely before use. The reagents listed below were dissolved in ddH20 and the solution 
was made up to 1 L. 
Tris 0.125 M 
Glycine 0.96M 
Sodium dodecyl sulphate (SDS) 0.5% 
B.4.2.2 GEL CASTING 
Resolving gels (12%) were prepared according to the protocol below and dispensed into 
an electrophoresis unit (SE410, Hoefer, San Francisco CA). 1.5% ammonium persul-
fate was prepared fresh immediately before use. Mter layering ddH20 over the top of 
the gel it was allowed to polymerise for approximately 1 h. 
Acrylamide/Bis Stock (30%T:2.7%C) 20 ml 
Resolving gel buffer 6.25 ml 
(3.0 M Tris'He!; pH 8.8) 
10% SDS 0.75 ml 
ddHzO 21.75 ml 
deaerate 1 min 
1.5% ammonium persulphate 1.5 ml 
TEMED 0.015 ml 
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The ddH20 layered over the gel was then removed and a 4% stacking gel was cast over 
the resolving gel. This was prepared according to the porto col described below. A comb 
was inserted into the stacking gel and it was allowed to polymerise for 30 min. The 
comb was then removed and the wells filled with reservoir buffer. 
AcrylamidelBis Stock (30%T:2.7%C) 2.5 ml 
Stacking gel buffer 5.0 ml 
(0.5 M Tris'HCli pH 6.8) 
10% SDS O.2ml 
11.3 ml 
deaerate 1 min 
1.5% ammonium persulphate 1.5 ml 
TEMED 0.015 ml 
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